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Troglitazone (TGZ) was an orally active thiazolidinedione (TZD) hypoglycemic agent 
which was used for the treatment of non–insulin–dependent diabetes mellitus and withdrawn 
from the market in 2000 due to its hepatotoxicity. Pioglitazone (PGZ) and rosiglitazone 
(RGZ), the other two analogues of the TZD ring are non–toxic and still in the market. While 
the exact mechanism of TGZ toxicity remains unknown, it has been postulated that the 
formation of toxic reactive metabolites (RMs) may play an important role in the 
hepatotoxicity. On the other hand, the sulfation at 6–hydroxyl group of the chroman ring of 
TGZ may be partially responsible for hepatotoxicity. PGZ and RGZ also produce RMs but 
they are non–toxic in nature due to lower doses. Few cases of hepatotoxicity of RGZ and 
PGZ had also been published recently. The purpose of this study is to investigate the role of 
sulfur moiety of the TZD nucleus in inducing liver toxicity. To achieve this goal, the TZD 
analogues were synthesized chemically where the sulfur moiety of the TZD ring was replaced 
by the methylene group of the pyrrolidinedione (PRD) ring. Both these analogues were 
incubated independently with human liver microsomes and glutathione (GSH). In a separate 
experiment, the TZD and PRD analogues were incubated with normal human hepatocytes 
(THLE-2 cells). Reactive metabolite glutathione (RM-GSH) adducts were formed during 
incubation which were separated by ultra performance liquid chromatography (UPLC) and 
identified using mass spectrometry (MS). 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium (MTT), glutathione (GSH) and protein carbonyl (PC) assays were 
performed to check the mechanism of toxicity of both these analogues using THLE–2 cells. 
Finally, peroxisome proliferator activated receptor gamma (PPARγ) binding activity and aP2 
gene expression assays were performed to check the binding affinities of both these 
analogues. Our results indicated collectively that the TZD analogues were more toxic than the 
XI 
 
PRD analogues in THLE–2 cells. As both analogues were shown to bind to PPARγ, the 
substitution of the TZD ring by the PRD ring may be beneficial from a drug design 
perspective.  
Furthermore, we synthesized sulfo–conjugated troglitazone (TGZS) and toxicity 
studies were performed using THLE–2 cells. Our MTT, GSH and PC results suggested that 
TGZS was more toxic than its parent TGZ and may be partially responsible for TGZ–induced 
hepatotoxicity via the oxidative stress mechanism.    
In conclusion, our study suggested that the TZD antidiabetic drugs may be partially 
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Chapter 1  
Introduction   
 
1.1 Hepatotoxicity and drug metabolism 
 
Drug-induced liver failure is a significant health problem throughout the world in the 
twenty-first century. At the same time, drug-induced liver injury is one of the most common 
reasons for the withdrawal of approved drugs from the market and accounts for 
approximately 50% of the total cases of acute liver failure in the United States (Lee, 2003). 
Recent evidence suggested that more than 600 drugs are associated with hepatotoxicity in the 
United States (Lee, 2003).  
The biotransformation of drugs takes place in the liver (both phase I and II). 
Cytochrome P450 enzymes (CYP450) are mainly responsible for the metabolism of most 
drugs and other xenobiotics. Different types of metabolites are generated from the 
biotransformation of drugs. One is the inactive metabolite which is relatively more polar in 
nature than the parent drug and easily eliminated via the renal system. Another is the highly 
electrophilic reactive metabolite (RM) which can interact with vital intracellular 
macromolecules resulting in toxicity. RMs are detoxified naturally through the binding with 
endogenous nucleophiles such as glutathione (GSH) and proteins. GSH can bind with RMs 
nonenzymatically or enzymatically by the action of glutathione S-transferases. When excess 
RMs bind covalently with cellular macromolecules (e.g. proteins and/or nucleic acids), 
serious toxicity may result (Fig. 1). Currently, the pharmaceutical industry has adopted the 















Fig. 1 Relationship between drug metabolism and toxicity. Toxicity may be acquired through 
either accumulation of parent drug or via metabolic activation, through formation of toxic 
RMs. If RMs are not detoxified, they can bind covalently with biological macromolecules 
which may lead to drug toxicity (Park et al., 2005).    
 
 
1.2 Role of metabolism in hepatotoxicity 
 
 The most prevalent hypothesis for metabolism related hepatotoxicity is the hapten 
carrier hypothesis (Park et al., 1998; Uetrecht., 1999). The hypothesis suggested that all small 
molecules are not immunogenic in nature. They produce immune response during binding to 
larger molecule like proteins. Drugs and their RMs act as hapten and bind with proteins and 
cellular molecules irreversibly to perform cellular toxicity.  
 Drug molecules were either withdrawn from market or given black box warning due 
to their potential cause of hepatotoxicity. Bromfenac, the second generation non-steroidal 
anti-inflammatory drug was withdrawn from market in 1998 due to the formation of acyl 
glucuronide conjugate during metabolism which might be reacted with hepatic proteins 
























(Rabkin et al., 1999). The antidepressant drug, nefazodone was withdrawn from market in 
2003 due to its hepatotxicity nature. It produced hydroxyl and quinonimine intermediates 
after metabolic activation which was trapped by GSH (Kalgutkar et al., 2005).  
 The anti-tubercular drug, isoniazid received black box warning in 1969 which 
generated acetylhydrazine after metabolic activation and might be reacted with cellular 
macromolecules (Nelson et al., 1976). The anti-fungal drug, ketoconazole was given black 
box warning in 1980 which produced N-desmethyl ketoconazole during metabolism and 
might be reacted with hepatic cells (Heel et al., 1982).   
Another classical example of drug induced hepatotoxicity is troglitazone which was 
used as antidiabetic drugs and withdrawn from market in 2000 (Chojkier, 2005). It produced 
sulfoxide and α–ketoisocyanate intermediates after metabolic activation which might have 
tendency to bind with GSH.  
 
1.3 Symptoms and treatment of diabetes mellitus   
 
Diabetes mellitus affected an estimated 16 million people in the United States  in 
1998 (Harris et al., 1998). At present, one out of eleven people (~ 10% of population) is 
affected by diabetes in Singapore (www.diabetes.org.sg). Type II diabetes mellitus (also 
known as non-insulin-dependent diabetes mellitus) is the fourth leading cause of death in the 
United States which is also a major contributor to blindness and chronic renal failure. The 
disease is linked to several long-term complications like retinopathy, nephropathy, 
neuropathy, hypertension, atherosclerosis, and hyperlipidemia (Bethesda, 1995; Harris et al., 
1998).  
Diagnosis and complications of diabetes mellitus have been described as a mixture of 
metabolic disorders which are characterized by hyperglycemia. There are several treatments 
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of diabetes mellitus comprising non-pharmacologic interventions such as diet modification 
and exercise and pharmacological interventions such as sulfonylureas, metformin, acarbose, 
2,4–thiazolidinediones (TZDs) and insulin administered either alone or in combination for the 
treatment of type II diabetes mellitus (UK Prospective Diabetes Study Group, 1998; 
American Diabetes Association, 2000).   
In the introduction, we focus our discussion on the TZD antidiabetic drugs as this 
group of drugs is implicated in hepatotoxicity via possible metabolic activation.  
  
1.4 Pharmacology and metabolism of TZD antidiabetic drugs  
 
Troglitazone (TGZ, Fig. 2) and the other TZD antidiabetic drugs such as rosiglitazone 
(RGZ, Fig. 2) and pioglitazone (PGZ, Fig. 2) lower the blood glucose concentration by partial 
agonism to peroxisome proliferator activated receptor gamma (PPARγ) (Henry, 1997). 
PPARγ is a ligand activated transcription factor which is similar to the retinoid X receptor 
(Zhang et al., 1992; Kliewer et al., 1992) and interacts with genes during glucose and lipid 
metabolism. Among the effects, researchers proposed that TGZ and RGZ induce human 
adipocyte fatty acid (aP2) binding protein gene expression in adipocytes (Kletzien et al., 
1992; Ibrahimi et al., 1994). Once PPARγ is stimulated, glucose transporter–4 production and 
translocation occur inside the cell system. As a result, TGZ and other glitazones may raise 
serum triglycerides level or alter thyroid metabolism (Miller et al., 1997; Sherman et al., 
1999; Rizvi et al., 1999) and inhibit phosphoenolpyruvate carboxylase enzyme, which is 
mainly responsible for hepatic gluconeogenesis (Camp et al., 2000). TGZ has no direct action 
on insulin formation and secretion, but increases the insulin sensitivity of adipose tissue and 
skeletal muscle during hyperglycemia and decreases hepatic glucose production (Wagstaff et 
al., 2002).  
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In vitro and in vivo experiments suggested that TGZ is mainly metabolized by 
cytochrome 3A4 (CYP3A4) and 2C8 (CYP2C8) enzymes (Sahi et al., 2000; Ramachandran 
et al., 1999; He et al., 2001). The metabolism of TGZ in liver includes oxidation (phase I 
metabolism), sulfation and glucuronidation (phase II metabolism). The glucuronide 
metabolite of TGZ is found in human plasma at very low concentration while the major 
metabolites of TGZ in humans are the sulfate (TGZS, 70%, Fig. 2) and quinone (10%) 
conjugates, respectively (Loi et al., 1997; Loi et al., 1999).  
RGZ is mainly metabolized by CYP2C8 and to a lesser extent by cytochrome 2C9 
enzyme (CYP2C9) in liver to the corresponding ortho- or para-hydroxyl and N-desmethyl 
RGZ (phase I metabolism). These metabolites are conjugated subsequently with sulfate and 
glucuronic acid (phase II metabolism) (Malinowski and Bolesta, 2000).  
PGZ is also oxidized by CYP2C8 and CYP3A4 to the corresponding hydroxyl and 
carboxyl metabolite of PGZ (phase I metabolism) (Jaakkola et al., 2005). These metabolites 
are excreted after sulfate and glucuronide conjugation (phase II metabolism).     
 
1.5 Potential mechanisms of TZD–induced hepatotoxicity  
 
TGZ was withdrawn from the market in 2000 due to fatalities caused by liver toxicity 
(Chojkier, 2005). While H2-receptor antagonists having thiazolidine ring (ebrotidine, 
famotidine) were also withdrawn form market due to similar toxic liabilities (Andrade et al., 
1999; Castillo et al., 2000), the other PPARγ agonists such as RGZ and PGZ which contain 
the TZD ring are still used clinically for the treatment of diabetes. However, RGZ was 
recently found to be associated with cardiotoxicity (Burce et al., 2007) and hepatic injury 
(four reports) (Park et al., 2005). On the other hand, there were also six reports of hepatic 
injury in the case of PGZ (Park et al., 2005; Baughmam et al., 2005). Nonetheless, there were 
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no severe case reports regarding the hepatotoxicity of PGZ and RGZ till date. Ciglitazone 
(CGZ, Fig. 2), another TZD antidiabetic drug candidate, was also withdrawn from phase-II 
clinical trial due to its poor efficacy (Day, 1999). The exact nature of TGZ inducing 
hepatotoxicity has not been established but many mechanisms had been proposed (Smith, 
2003). As TZD drugs are still used clinically, it becomes necessary to investigate the 
mechanism of toxicity of TGZ.  
 
1.6 Mechanism of TGZ-induced hepatotoxicity   
 
The exact nature of TGZ-induced hepatotoxicity has not been established, but many 
mechanisms had been proposed (Smith, 2003; Masubichi, 2006). These potential mechanisms 
include the formation of electrophilic reactive intermediates (section 1.6.1), direct binding to 
PPARγ (section 1.6.2), mitochondrial dysfunction (section 1.6.3), formation of TGZS (section 
1.6.4), apoptotic induction of hepatocytes and cancer cells (section 1.6.5) and a combination 
of host factors (section 1.6.6). All these proposed mechanisms are briefly discussed below. 
Sections 1.6.2, 1.6.3 and 1.6.5 are related to the direct toxicity of TGZ to liver cell, while 
sections 1.6.1 and 1.6.4 are related to the metabolism-based toxicity of TGZ.  
 
1.6.1 Formation of electrophilic reactive intermediates  
 
 Recently available data proposed that TGZ produces hepatotoxicity via the formation 
of RMs (Kassahun et al., 2001). One postulation was that the sulfur moiety of the TZD ring 
might be oxidized by CYP3A4 enzyme to the corresponding electrophilic sulfoxide and α–
ketoisocyanate intermediates that might react with GSH. Six reactive metabolite glutathione 



















Fig. 2 Structures of TZD antidiabetic drugs (A) TGZ (* 6-hydroxyl group of the chroman 








in vitro using human liver microsomes (HLM) and in vivo using Sprague-dawley rats 
((Kassahun et (Kassahun et al., 2001; Prabhu et al., 2002). Among these six RMs of TGZ, 
one was related to a quinone metabolite, while the other five RMs arose from the TZD 
moiety. The presence of a quinone metabolite appeared to be the potential cause of TGZ 
toxicity as the safer analogues such as RGZ and PGZ do not contain a chroman ring nor 
generate the quinone metabolite (Fig. 2). However, it had been shown that the quinone 
metabolite of TGZ was not as cytotoxic as compared to the parent drug in human and porcine 
hepatocytes (Tetty et al., 2001; Kostrubsky et al., 2000). On the other hand, all TZD drugs, 
including RGZ and PGZ, are capable of TZD-ring opening to generate reactive intermediates. 
Therefore, it becomes difficult to account for the higher level of toxicity of TGZ as compared 
to RGZ and PGZ. For example, RMs of RGZ and PGZ that are related to the TZD ring had 
been identified (Alvarez-Sánchez et al., 2006). Nonetheless, one must be mindful that RGZ 
and PGZ are prescribed at much lower doses clinically than TGZ (Malinowski and Bolesta, 
2000), and thus present a reduced risk for toxicity given a similar adduction potential. As the 
TZD ring may be implicated in toxicity due to the formation of reactive intermediates, it is 
important to question, investigate and understand the role of the TZD ring in toxicities related 
to this class of drugs. 
 
1.6.2 Direct binding to PPARγ 
 
 All the TZD antidiabetic drugs are specific ligands for PPARγ (Berger and Moller, 
2002; Hihi et al., 2002). PPARγ belongs to the nuclear receptor family that regulates the gene 
expressions during glucose and lipid metabolism. There are several postulations regarding the 
binding of TZD drugs to PPARγ which include alteration of glucose and lipid metabolism and 
changes in the expressed genes that control apoptosis, a form of cell suicide or cell death. 
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Apoptosis is manifested by cell shrinkage, nuclear and DNA fragmentation and removal of 
cells by phagocytosis. Apoptotic induction by TGZ in hepatocytes depends on its binding to 
PPARγ. While other TZD drugs (RGZ and PGZ) were shown to bind to PPARγ, they were 
found to be less toxic in inducing apoptosis in cultured liver cells in vitro (Lloyd et al., 2002).  
Therefore, direct binding to PPARγ may be another cause of TGZ-induced hepatotoxicity.  
 
1.6.3 Mitochondrial dysfunction 
 
 It had been shown that TGZ has direct effect on mitochondria producing depletion of 
adenosine-tri-phosphate and release of cytochrome c, which in turn induces cell death via 
apoptosis. TGZ had been shown to produce a rapid decline in mitochondrial membrane 
potential and adenosine-tri-phosphate depletion during its incubation with hepatocytes 
(Haskins et al., 2001). Therefore, mitochondrial dysfunction may be another possible 
outcome of TGZ-inducing hepatotoxicity.     
 
1.6.4 Formation of TGZS 
 
 The major metabolite of TGZ is TGZS (Loi et al., 1997; Loi et al., 1999). The phase 
II sulfation of TGZ occurs at the 6-hydroxyl group of its chroman ring (Fig. 2). While the 
formation of sulfate metabolites of TGZ and its billiary excretion form part of the drug 
elimination process, Kostrubsky et al. (2000) proposed that diabetic patients with cholestasis 
may have less capacity to excrete TGZS through the bile and the risk of hepatotoxicity may 
be increased.  
 Another probable mechanism of hepatotoxicity is the inhibition of bile salt export 
pump (BSEP) by TGZS causing accumulation of bile salts in the liver. As BSEP plays an 
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SG* = deprotonated GSH 
Fig. 3 RM–GSH conjugates of TGZ (M1-M5 and ML3) (Kassahun et al., 2001; Prabhu et al., 
2002).   
R =  






important role in removing bile salts from liver cells using energy in the form of adenosine-  
tri-phosphate (Kullak et al., 2000), the accelerated accumulation of bile salts may lead to 
cholestasis and subsequent hepatocyte apoptosis. High concentration of bile salt levels have 
been shown to induce liver cell death and mitochondrial dysfunction due to their detergent 
properties (Delzenne et al., 1992; Gores et al., 1998). The cholestatic potential of TGZ and 
TGZS had been studied previously in vitro and in vivo in rats (Funk et al., 2001). With the 
increasing findings of toxic phase II metabolites, it is also important to investigate and 
elucidate whether TGZS has any direct toxic effect on normal human hepatocytes besides 
BSEP inhibition. 
 
1.6.5 Apoptotic induction of hepatocytes and cancer cells 
 
 It has been shown that TGZ produces apoptotic induction of normal hepatocytes by 
activation of c-Jun N-terminal protein kinase and p53 mitogen ptotein kinase (Masubichi, 
2006). It releases cytochrome-c and declines mitochondrial membrane potential during 
incubation with normal human hepatocytes. It causes death of cancerous cells via either 
PPARγ activation or by changing the mitochondrial morphology (Masubichi, 2006).  
 
1.6.6 Host factors 
 
 Multiple host factors might have predisposed the patients to hepatotoxicity induced by 
TGZ. These factors include the presence of diabetes with ongoing cholestasis, the 
concomitant use of other cholestatic drugs, impaired liver function leading to low rates of 
drug metabolism and clearance, low CYP3A4 activity or inhibition of CYP3A4 activity by 
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other drugs, dietary factors and obesity/ hypertriglyceridemia/ insulin resistance syndrome 
leading to non-alcoholic steatohepatitis (Kawai et al., 1997; Kostrubsky et al., 2000). 
 
1.7 Quantitative structure activity relationship (QSAR) of TZD antidiabetic drugs 
 
TZD antidiabetic drugs have a few pharmacophoric elements which are essential for 
binding to PPARγ. Based on X–ray crystallographic study and molecular modeling, a U 
shaped pharmacophore had been identified for PPARγ agonists. The four heads of the TZD 
ring (S, NH and two C=O) are bound with PPARγ by hydrogen bonds (Khanna et al., 2005; 
Ramachandran et al., 2004). 
  QSAR study of TZD antidiabetic drugs exerted that both parts B and C are most 
essential for binding to the receptor (Fig. 4). On one hand, part A has various substitutions 
(TGZ – chroman, RGZ and PGZ – pyridine, and CGZ – cyclohexane ring) which appear to 
be not essential for binding to the receptor. On the other hand, the pyridine moiety of RGZ 
and PGZ enhance the binding affinity of these drugs to the receptor as compared to the 
chroman moiety of TGZ (Ramachandran et al., 2004). Comparative Molecular Field Analysis 
(CoMFA) data showed that when the sulfur moiety of TZD ring (part C) was substituted by 
oxygen moiety, there was no change in the IC50 of the substituted compounds (Momose et al., 
2002). Robert et al. (1991) had prepared some 2,4-oxazolidinedione derivatives as potent 
hypoglycemic agents with similar IC50 values like TZD antidiabetic drugs.  
 This substitution established an important finding that there was no significant change in 
the biological activity when the sulfur moiety of the TZD ring was replaced by the 
bioisosteric oxygen moiety. In view with the above findings, we replaced the sulfur moiety 












Fig. 4 Pharmacophoric elements of TZD antidiabetic drugs 
 
1.8 Research questions   
 
The above review raised two important research questions.  
 
 While all the TZD antidiabetic drugs possess the common TZD ring, TGZ is 
hepatotoxic and yet RGZ and PGZ demonstrate better safety profiles. The TZD ring is 
an important phamacophoric element but implicated in the formation of RMs (Fig 5). 
This raised the question of what is the role of the TZD ring in inducing hepatotoxicity.   
 TGZS is the major metabolite of TGZ in human plasma after the intravenous 
administration of parent TGZ. While the majority phase II metabolites are non-toxic, 
TGZS was found to inhibit BSEP and might be implicated in cholestasis (Fig 5). This 
raised an important question of whether TGZS exerts any direct toxic effect on human 




Part A Part C Part B 
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1.9 Hypothesis  
  
We hypothesize that the sulfur moiety of the TZD ring of glitazones and the phase II 
metabolite of TGZ, TGZS, are the toxicophores that may account for drug-induced toxicity in 
human. 
 
1.10 Objectives  
 
The overarching aim of my thesis is to investigate and elucidate the structural toxicity 
relationship (STR) of the TZD antidiabetic drugs with respect to human liver toxicity. The 
five key objectives of this project are summarized below.  
1. To synthesize and characterize the chemical analogues of the TZD antidiabetic drugs. 
These compounds were used for the STR study of TZD antidiabetic drugs. 
2. To screen and identify the RMs of the TZD drugs and their chemical analogues using 
liquid chromatography tandem mass spectrometry (LC/MS/MS). These experiments 
were performed to explore and ascertain the metabolic potential of these compounds 
in generating electrophilic intermediates. 
3. To characterize the cytotoxicities of the TZD drugs, their analogues using 
metabolically-active normal human hepatocytes (THLE-2 cells) (Andrea et al., 1993). 
Various cytotoxic assays were performed to elucidate the STR of the TZD drugs. 
4. To characterize the PPARγ binding affinities using the PPARγ ligand–binding domain 
(LBD) and measure aP2 gene expression using human adipose cells (3T3-L1) of the 
TZD drugs and their analogues. 
5. To synthesize and characterize TGZS and screen the cytotoxicities of TGZ and TGZS 
using THLE-2 cells.  
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1.10.1 Chemical synthesis of analogues of TZD antidiabetic drug  
 
The thia (-S-) group of TZD is implicated in the formation of RMs. In order to 
investigate the role of the TZD ring in inducing liver toxicity via the formation of RMs, 
chemical analogues of TGZ, RGZ, PGZ and CGZ where the TZD ring was replaced by the 
pyrrolidine–2,5–dione (PRD) ring, were synthesized and investigated (Fig. 5). In terms of 
physicochemical properties, the PRD (succinimide) ring shares similar five-membered ring 
structure, molecular size and lipophilicity (Table 1) with the TZD ring. On the other hand, the 
PRD ring lacks the -S- group and possesses the -CH2- group. The generated analogues 
namely, TSN, RSN, PSN and CSN (Table 1) were used subsequently for the STR studies and 
to ascertain if the isosteric replacement of the TZD with PRD ring affected the PPARγ-related 
biological effects.  
 
1.10.2 Screening and identification of RMs using LC/MS/MS  
 
Some xenobiotics can be metabolized by CYP450 enzymes to form RMs which bind 
covalently with GSH. In order to profile and identify RMs of the TZD antidiabetic drugs and 
the proposed synthetic PRD analogues, these compounds were incubated with HLM and 
GSH. In a separate experiment, the TZD and PRD analogues were incubated with THLE-2 
cells. Any RM-GSH adducts formed during incubation that were separated by ultra 




















































Table 1 TZD antidiabetic drugs (TGZ, RGZ, PGZ and CGZ) and the respective proposed 
PRD analogues (TSN, RSN, PSN and CSN). * Positions where TZD and PRD rings are 
covalently bonded to the structural back bones. Values in parentheses refer to the cLogP 






























1.10.3 Toxicity screening  
 
RMs can produce toxicity by redox cycling with molecular oxygen to produce 
superoxide anion radical and subsequent oxidative stress (Bolton et al., 2000; Thor et al., 
1982; Schulz et al., 1996). The formation of oxygen radicals may lead to GSH and protein 
oxidation and the peroxidation of membrane lipids. In addition to the profiling of RMs using 
LC/MS/MS, the TZD antidiabetic drugs and the PRD analogues were screened for toxicity in 
vitro using THLE-2 cells. MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium], GSH 
and protein carbonyl (PC) assays were performed as part of toxicity screening (Fig. 5). 
 
 1.10.4 Screening of PPARγ binding affinities and aP2 gene expression   
 
All TZD antidiabetic drugs are specific ligands for PPARγ. Determination of PPARγ 
binding activity of the TZD drugs and the PRD analogues were performed using PPARγ-LBD 
at 0 and 24 h. Various concentrations of the test compounds were incubated with PPARγ–
LBD for 24 h. Percentage of drug binding was measured using LC/MS/MS. 
It was postulated that all the TZD antidiabetic drugs exhibited their activity by 
activating PPARγ target genes, among which aP2 gene is a robust indicator (Kletzien et al., 
1992; Ibrahimi et al., 1994). It was also demonstrated that ap2 genes were expressed in 3T3-
L1 cells, a cell line that had similar morphological and biochemical pattern like human 
adipocytes (Kletzien et al., 1992). In my project, aP2 gene expression assays were performed 
of all the test compounds via polymerase chain reaction (PCR) and quantitative real-time 



































Fig. 5 Summary of the proposed research work  
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1.10.5 Synthesis and cytotoxicity screening of TGZ and TGZS 
  
The 6-hydroxy group of TGZ is responsible for the formation of TGZS. TGZS 
inhibits BSEP that might lead to subsequent cholestatis and hepatocyte injury. In order to 
investigate the involvement of the chroman ring of TGZ in inducing direct hepatotoxicity, 
TGZS was further synthesized to complement the STR study.  
 Similar cytotoxicity experiments (MTT, GSH and PC assays) were separately 




 The finding of this project establishes a correlation between toxicity effect and 
pharmacological response related to the TZD drugs. While structural changes leading to 
different pharmacological effect have been well studied in the context of antidiabetic drugs, 
much less is known about their impact on their toxicity. This study considers how chemical 
modification may contribute to both toxicological and pharmacological effects 
simultaneously. The knowledge generated can help support the future design of efficacious 
but less toxic antidiabetic agents. In our project, the structural modification involves changing 
the sulfur moiety with the bioisosteric methylene moiety. We believe that our data will 
provide useful information for the wider scientific community as they consider the use of 
such functional groups for other drug design.    
On a broader perspective, this study underscores the value of incorporating both 
structure activity relationship (SAR) and STR studies in the early stage of drug discovery, so 




1.12 Overview of proceeding chapters  
 
Chapter two will be focussed on the synthesis of the PRD analogues. Chapters three 
and four will investigate and discuss the potential mechanism of toxicity related to the TZD 
and PRD analogues. PPARγ binding activity and aP2 gene expression study will be discussed 
in chapter five while the comparison of hepatotoxicity between TGZS and TGZ will be 
discussed in chapter six. The conclusion related to my project will be featured in the final 

























Chapter two focuses mainly on the synthesis of the PRD analogues where the sulfur 
moiety of the TZD ring was replaced by the methylene moiety of the PRD ring. These two 
nuclei share similar five-member ring structure, molecular size and lipophilicity (discussed in 
chapter one).      
 The TZD antidiabetic drugs are generally prepared by the following procedures as 
described below. Etherification was performed using Williamson ether synthesis where ether 
linkages were formed between alcohol and p-fluorobenzaldehyde in presence of strong base. 
Later, TZD ring was reacted with corresponding aldehyde in presence of basic amines to 
form -ene- compounds (Knoevenagel synthesis). Finally, reduction step was conducted in 
presence of 10% palladium–charcoal (Pd/C) and hydrogen atmosphere to get desired TZD 
compounds (Lee et al., 2005; Fan et al., 2004; Huang et al., 2006).    
The PRD analogues were prepared as outlined in Fig. 7 to 14 using the procedures 
described below. For all the chemical analyses of synthesized intermediates and final 
products, proton nuclear magnetic resonance (1H NMR) and carbon nuclear magnetic 
resonance (13C NMR) spectra were recorded on a Bruker 300 MHz NMR spectrometer 
(Rheinstetten, Germany) using deuterated dimethyl sulfoxide (DMSO-d6) (2.5 and 40.0-41.1 
ppm for 1H and 13C, respectively) and deuterated chloroform (CDCl3) (7.26 and 76.6-77.4 
ppm for 1H and 13C, respectively) as solvent peaks. Direct-infusion mass spectroscopy (MS) 
data were acquired using a hybrid triple quadrupole linear ion trap MS (QTRAP MS) 
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equipped with an electrospray ionization (ESI) source (2000 QTRAP, Applied Biosystems, 

























Fig. 6 General procedure for the synthesis of TZD antidiabetic drugs. (A) sodium hydride, 
anhydrous DMF, 4-flurobenzaldehyde, RT, 12 h; (B) TZD, piperidine, ethanol, reflux, 24 h; 
(C) 10% Pd/C, hydrogen gas, ethanol, 12 h.  
 
   
2.2 Materials 
 
HPLC-grade acetonitrile (ACN) was purchased from Tedia Company Inc. (Fairfield, 
OH, USA). Formic acid (99% purity) and glacial acetic acid were purchased from VWR 
International Ltd. (Leicestershire, UK). DMSO (ACS grade) was obtained from Panreac 
Quimica SA (Barcelona, Spain). Dichloromethane was purchased from Merck (Merck Pte. 
Ltd., Singapore). Water was purified using a Milli-Q water purification system (Millipore, 
Bedford, MA, USA). All the other chemicals related to the synthesis of the PRD analogues 
were purchased from Sigma-Aldrich (Saint Louis, MO, USA). All other reagents and 





2.3 Preparation of TSN (C25H29NO5) 
 
The synthetic routes of TSN are illustrated in Fig. 7.  
 
2.3.1 Synthesis of 3-(triphenylphosphoranylidene)pyrrolidine-2,5-dione [I (A)] 
 
A mixture of maleimide (1 g, 10.30 mmol), triphenylphosphine (2.70 g, 10.30 mmol) 
and acetone (30 mL) was heated under reflux for 1 h. After cooling, the resulting precipitate 
was filtered, washed with acetone (100 mL) and recrystallized using acetone. The crystal was 
filtered and dried under vacuum at 40°C overnight to give a white solid [I (A)] (Fig. 7) (2.8 g, 
yield 75%). Melting point 227°C. 1H NMR (DMSO-d6) δ: 4.76 (s, 2H, -CH2-),  7.58-7.64 (m, 
15H, -C6H5), 8.67 (s, 1H, >NH).  MS (ESI+) m/z (M+H)+ 360.3.  
 
2.3.2 Synthesis of methyl-6-hyroxy-2,5,7,8-tetramethylchroman-2-carboxylate [II (A)] 
 
 A mixture of paraformaldehyde (0.99 g, 32.8 mmol), methyl methacrylate (17.44 mL, 
164 mmol), dibutylamine (0.7 mL, 3.92 mmol) and 25 mL acetic acid were stirred at room 
temperature (28 ± 4°C) for 30 min and 2,3,5-trimethylbenzene-1,4-diol (5 g, 32.8 mmol) was 
added to it. Then the mixture was heated under reflux for another 24 h and cooled to RT. The 
reaction mixture was kept at 4°C overnight to promote crystal formation. The resulting 
crystal was filtered, recrystallized with methanol (20 mL) and dried under vacuum 
at 40°C to give a white solid [II (A)] (Fig. 7) (4.2 g, 48% yield). Melting point 160-162°C. 1H 
NMR: (DMSO-d6) δ: 1.50 (s, 3H, -CH3), 1.73-1.80 (m, 1H, -CH2-), 1.97 (s, 3H, -CH3), 2.03 
(s, 3H, -CH3), 2.05 (s, 3H, -CH3), 2.27-2.38 (m, 2H, -CH2-), 2.55-2.58 (m, 1H, -CH2-), 3.20 
(s, 3H, -OCH3), 7.48 (s, 1H, -OH). 13C NMR: (DMSO-d6) δ: 11.65, 11.70, 12.62, 20.32, 
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Fig. 7 Synthesis of TSN. (A) Triphenylphosphine, methanol, reflux, 1.5 h; (B) dibutylamine, 






























allyl bromide, acetone AR, potassium carbonate, reflux, 48 h; (E) sodium hydride, anhydrous 
DMF, 4-flurobenzaldehyde, RT, 12 h; (F) 3-(tripehnyphosphoranylidene)pyrrolidine-2,5-
dione, methanol, reflux, 3 h; (G) lithium chloride (anhydrous), sodium borohydride, 
anhydrous THF, RT and 10% Pd/C, hydrogen gas, ethanol, 12 h.  
 
 
    


































Fig. 8 13C NMR interpretation of (A) methyl-6-hyroxy-2,5,7,8-tetramethylchroman-2-
carboxylate, (B) 4-((6-(allyloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)benzaldehyde 
and (C) TSN.  
 
 
25.05, 30.08, 52.08, 99.52, 116.27, 120.10, 120.79, 122.61, 144.55, 145.55 and 173.38 (Fig. 
8A). MS (ESI+) m/z (M+H)+ 265.3.    
 
2.3.3 Synthesis of 2-(hydroxymethyl)-2,5,7,8-tetramethylchroman-6-ol [II (B)] 
 
A solution of methyl-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylate (4 g, 16.9 






of lithium aluminium hydride (0.644 g, 16.9 mmol) in anhydrous THF (10 mL) under 
nitrogen atmosphere at 0°C over 30 min. It was stirred for another 6 h under nitrogen 
atmosphere at RT. The reaction mixture was quenched using 0.25 N sodium hydroxide (5 
mL). Subsequently, the mixture was stirred for 1 h at RT, filtered and concentrated by 
evaporation under reduced pressure. The concentrate thus obtained was purified by column 
chromatography on silica gel (60–120 mesh) using a mixture of n–hexane/ethyl acetate 
(EtOAc) (2:1 v/v) as eluent to give a white solid [II (B)] (Fig. 7) (2.4 g, 67% yield). Melting 
point 183°C. 1H NMR: (DMSO-d6) δ: 1.12 (s, 3H, -CH3), 1.59-1.68 (m, 1H, -CH2-), 1.76-
1.85 (m, 1H, -CH2-), 1.96 (s, 3H, -CH3), 2.00 (s, 3H, -CH3), 2.03 (s, 3H, -CH3), 3.27-3.29 (m, 
2H, -CH2-), 3.9-4.3 (m, 1H, -CH2-), 4.82 (t, 1H, J=6 Hz, -CH2-), 7.41 (s, 1H, -OH). MS 
(ESI+) m/z (M+H)+ 237.1.   
 
2.3.4 Synthesis of (6-(allyloxy)-2,5,7,8-tetramethylchroman-2-yl)methanol [II (C)] 
 
 A mixture of 2-(hydroxymethyl)-2,5,7,8-tetramethylchroman-6-ol (2.3 g, 9.74 mmol), 
allyl bromide (1.8 mL, 19.4 mmol) and anhydrous potassium carbonate (2.68 g, 19.4 mmol) 
in 20 mL acetone was refluxed for 48 h. The reaction mixture was cooled to RT, filtered and 
concentrated by evaporation under reduced pressure. The resulting concentrate was further 
purified by column chromatography on silica gel (60–120 mesh) using a mixture of n–
hexane/EtOAc (5:1 v/v) as eluent to give a white solid [II (C)] (Fig. 7) (1.9 g, 70% yield). 
Melting point 78–79°C. 1H NMR: (CDCl3) δ: 1.23 (s, 3H, -CH3), 1.68-1.74 (m, 1H, -CH2-),  
1.98-2.04 (m, 1H, -CH2-), 2.09 (s, 3H, -CH3), 2.14 (s, 3H, -CH3), 2.18 (s, 3H, -CH3), 2.64 (t, 
2H, J=9 Hz, -CH2-), 3.61 (d, 2H, J=6 Hz, -CH2-), 4.18 (d, 2H, J=6 Hz, -OCH2-), 5.24 (d, 1H, 




2.3.5 Synthesis of 4-((6-(allyloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)benzaldehyde [II 
(D)] 
 
Sodium hydride (60% in mineral oil, 0.315 g, 13.04 mmol) and 6-(allyloxy)-2,5,7,8-
tetramethylchroman-2-yl)methanol (1.8 g, 6.52 mmol) in anhydrous dimethylformamide 
(DMF) (20 mL) was stirred for 30 min under nitrogen atmosphere at RT. Subsequently, 4–
fluorobenzaldehyde (1.4 mL, 13.04 mmol) was added slowly dropwise to the reaction 
mixture under nitrogen atmosphere at RT. After stirring at the same temperature for 
overnight, the reaction mixture was quenched with aqueous ammonium chloride (20 mL). 30 
mL of ice–water (30 mL) was added and the resultant mixture was extracted with EtOAc (50 
mL, two times). The organic layer was washed with water and brine, dried over anhydrous 
sodium sulfate and concentrated by evaporation under reduced pressure. The concentrate thus 
obtained was purified by column chromatography on silica gel (60–120 mesh) using a 
mixture of n-hexane/EtOAc (4:1 v/v) as eluent to give a yellow liquid [II (D)] (Fig. 7) (0.41 
g, 16.1% yield). 1H NMR: (CDCl3) δ: 1.24-1.29 (m, 1H, -CH2-), 1.44 (s, 3H, -CH3), 1.94-
2.01 (m, 1H, -CH2-), 2.08 (s, 3H, -CH3), 2.15 (s, 3H, -CH3), 2.19 (s, 3H, -CH3), 2.62 (t, 2H, 
J=6 Hz, -CH2-), 3.99-4.12 (m, 2H, -CH2-), 4.19 (d, 2H, J=6 Hz, -OCH2-), 5.24 (d, 1H, J=12 
Hz, =CH2), 5.46 (d, 1H, J=18 Hz, =CH2), 6.06-6.11 (m,  1H, =CH-), 7.03 (d, 2H, J=6 Hz, -
C6H4-), 7.81 (d, 2H, J=6 Hz, -C6H4-), 9.88 (s, 1H, -CHO). 13C NMR: (DMSO-d6) δ: 11.84, 
11.97, 12.82, 14.19, 20.17, 22.59, 28.47, 72.89, 73.78, 74.13, 115.00, 116.82, 117.29, 122.96, 
126.07, 128.33, 130.10, 131.90, 134.29, 147.14, 148.80, 164.04 and 190.71 (Fig. 8B). MS 
(ESI+) m/z (M+H)+ 381.4. 
  
2.3.6 Synthesis of (E)-3-(4-((6-(alloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)benzyli- 
dene)pyrrolidine-2,5-dione [II (E)] 
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A mixture of 3-(triphenylphosphoranylidene)pyrrolidine-2,5-dione (370 mg, 1.04 
mmol), 4-((6-(allyloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)benzaldehyde (400 mg, 
1.04 mmol) in methanol (20 mL) was heated under reflux for 1.5 h and then cooled at RT. 
The reaction mixture was concentrated by evaporation under reduced pressure. The 
concentrate thus obtained was further purified by column chromatography on silica gel (60–
120 mesh) using a mixture of n–hexane/EtOAc (3:1 v/v) as eluent to give a white solid [II 
(E)] (Fig. 7) (0.21 g, 41.4% yield). Melting point 122–123°C. 1H NMR: (CDCl3) δ: 1.43 (s, 
3H, -CH3), 1.94-2.01 (m, 1H, -CH2-), 2.07 (s, 3H, -CH3), 2.14 (s, 3H, -CH3), 2.18 (s, 3H, -
CH3), 2.61 (t, 2H, J=6 Hz, -CH2-), 3.56 (s, 2H, -CH2-), 3.94-4.06 (m, 2H, -CH2-), 4.18 (d, 2H, 
J=6 Hz, -OCH2-), 5.24 (d, 1H, J=9 Hz, =CH2), 5.46 (d, 1H, J=18 Hz, =CH2), 6.05-6.11 (m, 
1H, -CH=), 6.98 (d, 2H, J=9 Hz, -C6H4-), 7.43 (d, 2H, J=6 Hz,  -C6H4-), 7.55 (s, 1H, -CH=), 
9.04-9.13 (br s, 1H, >NH). MS (ESI+) m/z (M+H)+ 462.3.  
 
2.3.7 Synthesis of (R,S)-3-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy)benzyl) 
pyrrolidine-2,5-dione (TSN) [II (F)] 
 
Lithium chloride (20 mg, 0.433 mmol) in anhydrous THF (10 mL) was taken into a 
two–necked round bottom flask at 0°C under nitrogen atmosphere. Sodium borohydride (25 
mg, 0.433 mmol) was added to the mixture very quickly. The reaction mixture was stirred for 
5 min and (E)-3-(4-((6-(alloxy)-2,5,7,8-tetramethylchroman-2-yl)methoxy)benzylidene) 
pyrrolidine-2,5-dione (150 mg, 0.433 mmol) in anhydrous THF (5 mL) was added to it 
dropwise with constant stirring. After complete addition, the reaction mixture was brought to 
RT and stirred for another 30 min. The reaction mixture was quenched with 2 mL water and 
evaporated to dryness under reduced pressure. 5 mL of water was added to reaction mixture 
and liquid–liquid extraction (LLE) was performed with ether (20 mL, 2 times). The ether 
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layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to 
form a yellow liquid. Next, the reduction step was performed without further purification. 
The above–mentioned liquid was dissolved in 20 mL ethanol taken in a parr bottle and 50 mg 
of (Pd/C) (10%) was added to it. The compound was hydrogenated under hydrogen 
atmosphere (pressure 40 psi) at RT for 8 h. The mixture was filtered using celite and 
concentrated by evaporation under reduced pressure to give a white solid. The compound was 
further purified by column chromatography on silica gel (60–120 mesh) using a mixture of n–
hexane/EtOAc (10:1 v/v) as eluent to give a white solid [II (F)] (Fig. 7) (0.5 g, 10.2% yield, 
98.7% purity). Melting point 205–207°C. 1H NMR: (CDCl3) δ: 1.42 (s, 3H, -CH3), 2.08 (s, 
3H, -CH3), 2.13 (s, 3H, -CH3), 2.18 (s, 3H, -CH3), 2.43-2.51 (m, 1H, -CH2-), 2.60-2.64 (m, 
2H, -CH2-), 2.68-2.74 (m, 1H, -CH2-), 2.84-2.89 (m, 1H, -CH<), 3.14 (d, 2H, J=12 Hz, -CH2-
), 3.61 (t, 2H, J=6 Hz, -CH2-), 3.85 (d, 1H, J=9 Hz, -CH2-), 3.95 (d, 1H, J=9 Hz, -CH2-), 6.85 
(d, 2H, J=9 Hz, –C6H4-), 7.07 (d, 2H, J=6 Hz, -C6H4-), 8.80 (s, 1H, >NH), 13C NMR: 
(DMSO–d6) δ: 10.71, 11.84, 12.73, 20.23, 22.89, 23.52, 28.54, 35.33, 42.88, 74.27, 74.65, 
115.11, 117.44, 122.84, 126.02, 128.27, 128.94, 130.04, 147.16, 148.80, 158.36, 175.85 and 
178.93 (Fig. 8C). MS (ESI–) m/z (M–H)– 422.0. 
 
2.4 Preparation of PSN (C20H22N2O3) 
 
The synthetic routes of PSN are illustrated in Fig.9.  
 
2.4.1 Synthesis of 4-[2-(5-ethylpyridine-2-yl)ethoxy]benzaldehyde [III (A)] 
 
 To a suspension of sodium hydride (60% mineral oil, 222 mg, 9.26 mmol) in anhydrous 
DMF (20 mL), 2-(5-ethylpyridine-2-yl)ethanol (700 mg, 4.63 mmol) was added and the 
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mixture was stirred for 30 min. Subsequently, 4-fluorobenzaldehyde (1 mL, 9.26 mmol) was 
added slowly to the reaction mixture under nitrogen atmosphere at RT. After stirring at the 
same temperature for 3 h, the reaction mixture was quenched with aqueous ammonium 
chloride (20 mL), poured into ice-water (30 mL), and extracted with EtOAc (80 mL). The 
extract was washed with water and brine (50 mL, 2 times), dried over anhydrous sodium 
sulfate and concentrated by evaporation under reduced pressure. The concentrate thus 
obtained was purified by column chromatography on silica gel (60–120 mesh) using a 
mixture of n–hexane/EtOAc (4:1 v/v) as eluent to give a yellow liquid [III (A)] (Fig. 9) 
(0.398 g, 57% yield).  1H NMR (DMSO–d6) δ: 1.17 (t, 3H, J=9, 15 Hz, -CH3), 2.57 (q, 2H, 
J=9 Hz, -CH2-), 3.18 (t, 2H, J= 6 Hz, -CH2-), 4.46 (t, 2H, J =6 Hz, -OCH2-), 7.10 (d, 2H, J=9 
Hz, -C6H4-), 7.30 (d, 1H, J=9 Hz, -C5H3N-),  7.57 (d, 1H, J=9 Hz, -C5H3N-), 7.83 (d, 2H, J=6 
Hz, -C6H4-), 8.37 (s, 1H, -C5H3N-),  9.85 (s, 1H, -CHO). MS (ESI) m/z (M+H)+ 256.3.  
 
2.4.2 Synthesis of (3E)-3-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzylidene}pyrrolidine-2,5-
dione [III (B)] 
 
 A mixture of 3-(triphenylphosphoranylidene)pyrrolidine-2,5-dione (250 mg, 0.69 
mmol), 4-[2-(5-ethylpyridin-2-yl)ethoxy]benzaldehyde (175 mg, 0.69 mmol) and methanol 
(20 mL) was heated under reflux for 1.5 h and then cooled at RT. The resulting crystal was 
filtered, washed with methanol (20 mL) and dried under vacuum at 40°C to give a white solid 
[III (B)] (Fig. 9) (0.33g, 98% yield). Melting point 224°C. 1H NMR (DMSO–d6) δ: 1.23 (t, 
3H, J=9, 15 Hz, -CH3), 2.76 (q, 2H, J=9 Hz, -CH2-), 3.48 (t, 2H, J=9 Hz, -CH2-), 3.59 (s, 2H, 
-CH2-), 4.48 (t, 2H, J=9 Hz, -OCH2-), 7.01 (d, 2H, J=6 Hz, -C6H4-), 7.32  (s, 1H, –CH=), 7.55 
(d, 2H, J=6 Hz, -C6H4-), 7.95 (d, 1H, J=9 Hz, -C5H3N-), δ:  8.37 (d, 1H, J=6 Hz, -C5H3N-), δ: 
8.71 (s, 1H, -C5H3N-), δ:  11.36 (s, 1H, >NH). 13C NMR (DMSO-d6) δ: 14.56, 24.53, 32.52, 
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Fig. 9 Synthesis of PSN. (A) 4-Flurobenzaldehyde, sodium hydride, DMF, RT, 12 h; (B) 3-
(triphenylphosphoranylidene)pyrrolidine-2,5-dione, methanol, reflux, 2 h; (C) 10% Pd/C, 

















































Fig. 10 13C NMR interpretation of (A) (3E)-3-{4-[2-(5-ethylpyridin-2 yl)ethoxy] 












34.64, 65.69, 114.93, 126.62, 127.10, 127.50, 131.13, 131.90, 140.82, 144.25, 151.33 159.02, 
150.09, 171.96, 175.67 (Fig. 10A). MS (ESI) m/z (M+H)+ 337.2. 
 
2.4.3 Synthesis of (R,S)-3-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}pyrrolidine-2,5-dione 
(PSN) [III (C)] 
 
  A solution of (3E)-3-{4-[2-(5-ethylpyridin-2yl)ethoxy]benzylidene}pyrrolidine-2,5-
dione (100 mg, 0.296 mmol) in ethanol (20 mL) was taken in a parr bottle and 50 mg of Pd/C 
(10%) was added to it.  The compound was hydrogenated under hydrogen atmosphere 
(pressure 5 psi) at RT for 8 h. The mixture was filtered using celite and concentrated by 
evaporation under reduced pressure to give a red colour solid [III (C)] (Fig. 9). (0.98 g, 98% 
yield, 98.3% purity). 1H NMR (CDCl3) δ: 1.32 (t, 3H, J=6 Hz, -CH3), 2.47 (d, 2H,  J=6 Hz, -
CH2-), 2.75 (m, 1H, -CH<), 2.88 (q, 2H, J=15 Hz, -CH2-), 3.13 (t, 2H, J=9 Hz, -CH2-), 3.57 
(d, 2H, J=6 Hz, -CH2-), 4.41 (t, 2H, J=9 Hz, -OCH2-), 6.83 (d, 2H, J=9 Hz, -C6H4-), 7.05 (d, 
2H, J=9 Hz, -C6H4-), 7.63 (d, 1H, J=9 Hz, -C5H3N-), 7.88 (s, 1H, -C5H3N-),  δ: 7.95 (d, 1H, 
J=9 Hz, -C5H3N-),  δ: 8.49 (s, 1H, >NH). 13C NMR (CDCl3) 14.57, 25.67, 34.27, 35.29, 
42.78, 66.14, 114.92, 126.37, 130.05, 130.21, 132.05, 140.31, 141.99, 142.54, 153.08, 
157.28, 176.54, 176.57 (Fig. 10B). MS (ESI) m/z (M+H)+ 339.2. 
 
2.5 Preparation of RSN (C19H21N3O3) 
 






2.5.1 Synthesis of tert-butyl (2-hydroxyethyl)methylcarbamate [IV (A)] 
 
 A solution of di-tert-butyl dicarbonate (3.7 mL, 16 mmol) in chloroform (10 mL) was 
added dropwise to a solution of 2-(methylamino)ethanol (1.3 mL, 16 mmol) in chloroform 
(10 mL) at 0°C. The mixture was stirred for another 24 h at RT and concentrated to dryness. 
The residue was a colourless oil [IV (A)] (Fig. 11) which was not purified in this step (2.5 g, 
89.3% yield). 1H NMR (CDCl3) δ: 1.37 (9H, s, Me3C-), 2.79 (s, 3H, >N-CH3), 3.19 (t, 2H, 
J=6 Hz, -CH2-), 3.36 (br s, 1H, -OH), 3.45 (t, 2H, J=6 Hz, -OCH2-). MS (ESI) m/z (M+H)+ 
176.0.   
  
2.5.2 Synthesis of tert-butyl [2-(4-formylphenoxy)ethyl]methylcarbamate [IV (B)] 
 
 Tert-butyl (2-hydroxyethyl)methylcarbamate (1 g, 6.21 mmol), 4-hydroxybenzalde- 
hyde (760 mg, 6.21 mmol) and triphenylphosphine (895 mg, 6.82 mmol) were added together 
in dry THF (25 mL) and the mixture was stirred for 30 min at 0°C. Diisopropyl 
azodicarboxylate (0.7 mL, 6.82 mmol) was added dropwise to the mixture over 15 min at 
0°C. It was stirred for 18 h at RT. THF was removed under reduced pressure and EtOAc (100 
mL) was added to it. The EtOAc layer was washed with 1N sodium hydroxide (20 mL), 
water (25 mL) and brine (20 mL). The organic layer was dried using anhydrous sodium 
sulfate and concentrated. The product was purified by silica gel column chromatography (60–
120 mesh) using n-hexane/EtOAc (4:1) to give the compound as a yellow liquid  [IV (B)] 
(Fig.11) (0.5 g, 31.34% yield). 1H NMR (CDCl3) δ: 1.43 (s, 9H, Me3C-), 2.96 (s, 3H,  >N-
CH3), 3.60 (t, 2H, J=9 Hz, -CH2-), 4.08 (t, 2H, J=9 Hz, -OCH2-), 6.96 (d, 2H, J=9 Hz, -C6H4-





                
                                                                  
                                         
                                              
 
Fig. 11 Synthesis of RSN. (A) Di-tert-butyl dicarbonate, chloroform, RT, 24 h; (B) 4-
hydroxybenzaldehyde, triphenylphosphine, diisopropyl azodicarboxylate, dry THF, 0°C, RT, 
18 h; (C) 3-(triphenylphosphoranylidene)pyrrolidine-2,5-dione, methanol, reflux, 2 h; (D) 
10% Pd/C, hydeogen gas, ethanol, 12 h; (E) 0.5N HCl in dioxane, chloroform, RT, 2 h; (F) 2-















































2.5.3 Synthesis of tert-butyl (2-{4-[(E)-(2,5-dioxopyrrolidin-3-ylidene)methyl]phenoxy}ethyl) 
methylcarbamate [IV (C)] 
  
A mixture of 3-(triphenylphosphoranylidene)pyrrolidine-2,5-dione (255 mg, 0.717 
mmol), tert-butyl [2-(4-formylphenoxy)ethyl]methylcarbamate (200 mg, 0.717 mmol) and 
methanol (20 mL) was heated under reflux for 1.5 h and then cooled at RT. The reaction 
mixture was kept at 4°C overnight to promote crystallization. The resulting crystal was 
filtered, washed with methanol (20 mL) and dried under vacuum at 40°C to give a white solid 
[IV (C)] (Fig. 11) (0.23 g, 92% yield). Melting point 242°C. 1H NMR (DMSO-d6) δ: 1.39 (s, 
9H, Me3C-), 2.96 (s, 3H, >N-CH3), 3.54 (t, 2H, J=9 Hz, -CH2-), 3.60 (s, 2H, -CH2-), 4.14 (t, 
2H, J=9 Hz, -OCH2-), 7.04 (d, 2H, J=6 Hz, -C6H4-), 7.33 (s, 1H, –CH=), 7.58 (d, 2H, J=6 Hz, 
-C6H4-), 11.34 (s, 1H, -NH-). MS (ESI) m/z (M+H)+ 361.1.    
 
2.5.4 Synthesis of tert-butyl 2-(4-((2,5-dioxopyrrolidin-3-yl)methyl)phenoxy) ethyl(methyl) 
carbamate [IV (D)] 
  
A solution of tert-butyl (2-{4-[(E)-(2,5-dioxopyrrolidin-3-ylidene)methyl]phenoxy} 
ethyl)methylcarbamate (200 mg, 0.055 mmol) in absolute ethanol (20 mL) was taken in a 
parr bottle and 50 mg of Pd/C (10%) was added to it.  The compound was hydrogenated 
under hydrogen atmosphere (pressure 40 psi) at RT for 8 h. The mixture was filtered using 
celite and concentrated by evaporation under reduced pressure to give a white solid [IV (D)] 
(Fig. 11) (0.195 g, 97.5% yield). Melting point 202–203°C. 1H NMR (CDCl3) δ: 1.44 (s, 9H, 
Me3C-), 2.70 (d, 2H, J=9 Hz, -CH2-), 2.85 (d, 2H, J= 9 Hz, –CH2–), δ: 3.07 (s, 3H, >N-CH3), 
3.43 (t, 2H, J=9 Hz, -CH2-), 3.50 (t, 2H, J=9 Hz, -OCH2-), 4.02 (m, 1H, -CH<), 6.82 (d, 2H, 
J=9 HZ, -C6H4-),  7.02 (d, 2H, J=9 HZ, -C6H4-). MS (ESI) m/z (M+H)+ 363.1.      
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2.5.5 Synthesis of 3-{4-[2-(methylamino)ethoxy]benzyl}pyrrolidine-2,5-dione [IV (E)]  
 
 0.5 N hydrochloric acid in dioxane (10 ml) was added to a solution of tert-butyl 2-(4-
((2,5-dioxopyrrolidin-3-yl)methyl)phenoxy) (195 mg) in chloroform (20 mL) under nitrogen 
atmosphere at 0°C. The mixture was stirred at RT for another 2 h. The chloroform layer was 
separated and evaporated to dryness to give the white colour solid compound [IV (E)] (Fig. 
11) (0.13 g, 89% yield). Melting point 223°C. 1H NMR (CDCl3) δ:, 1.98 (s, 1H, -NH-), 2.06 
(s, 3H, -CH3), 2.36 (d, 2H, J=6 Hz, -CH2-), 2.95 (d, 2H, J=6 Hz, -CH2-), 3.59 (t, 2H, J=9 Hz, 
>N-CH2-), 3.88 (t, 2H, J=9 Hz, -OCH2-), 4.32 (m, 1H, -CH<), 7.08 (d, 2H, J=9 Hz, -C6H4-), 
7.56 (d, 2H, J=9 HZ, -C6H4-), 11.38 (s, 1H, -NH-). MS (ESI) m/z (M+H)+ 263.1.  
 
2.5.6 Synthesis of (R,S)-3-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)pyrrolidine-2,5-
dione [IV (F)] 
  
2-Chloropyridine (0.2 mL, 1.7 mmol) was added to a stirred solution of 3-{4-[2-
(methylamino)ethoxy]benzyl}pyrrolidine-2,5-dione (150 mg, 0.517 mmol) in anhydrous 
ethanol and it was refluxed for 24 h. The reaction mixture was cooled to RT and concentrated 
under reduced pressure. The reaction mixture was quenched with ammonium chloride (50 
mL) and extracted with EtOAc (100 mL).  The extracted organic layer was washed with 
water (30 mL), brine (50 mL) and dried by anhydrous sodium sulfate. The organic layer was  
concentrated under reduced pressure and the residue was purified by silica gel column 
chromatography (60-120 mesh) using n-hexane/EtOAc (1:1 v/v) as an eluent to give a white 
solid compound [IV (F)] (Fig. 11) (0.12 g, 53% yield, 99.7% purity). Melting point 234°C. 
1H NMR (DMSO-d6) δ: 2.62 (d, 2H, J=6 Hz,-CH2-), 3.02 (s, 3H, >N-CH3), 3.34 (d, 2H, J=6 
Hz, -CH2-), 3.53 (m, 1H, -CH<), 4.14 (t, 2H, J=9 Hz, >N-CH2-), 4.24 (t, 2H, -OCH2-), 6.71 
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(d, 2H, J=9 Hz, -C6H4-), 7.15 (d, 1H, J=9 Hz, -C5H4N), 7.43 (d, 2H, J=9 Hz, -C6H4-), 7.53 
(dd. 1H, J=9 Hz, -C5H4N), 7.85 (dd, 1H, J=9 Hz, -C5H4N), 8.14 (d, 1H, J=9 Hz, -C5H4N), 
11.10 (s, 1H, >NH). 13C NMR (DMSO-d6) 32.64, 34.12, 34.32, 42.11, 47.18, 63.10, 114.50, 
123.07, 124.38, 130.00, 130.79, 139.80, 149.92, 150.19, 156.27, 177.88 & 180.83 (Fig. 12). 
MS (ESI) m/z (M+H)+ 340.1.   
 
2.6 Preparation of CSN (C19H25NO3)  
 
The synthetic routes of CSN are summarized in Fig. 13.  
 
2.6.1 Synthesis of (1-methylcyclohexyl)methanol [V (A)] 
  
A solution of iodine (5.3 g, 21 mmol) in anhydrous THF (20 mL) was added dropwise 
to a stirred solution of sodium borohydride (1.5 g, 4.18 mmol) in anhydrous THF (10 mL)  
under nitrogen atmosphere at 0°C over 30 min. Next, 1-methylcyclohexanecarboxylic acid (2 
g, 14.0 mmol) in THF (5 mL) was added to it and the mixture was stirred for another 4 h at 
RT. The reaction mixture was then cooled to 0°C and excess hydride was quenched by dry 
methanol (10 mL). The whole mixture was concentrated by evaporation under reduced 
pressure. 40 mL of 20% solution of potassium hydroxide was added to it and the mixture was  
extracted with ether (100 mL) two times. Each ether layer was washed with sodium 
thiosulfate solution and then with brine solution. The combined ether layer was dried under 
anhydrous sodium sulfate and concentrated under reduced pressure. The crude product was 
purified by silica gel column chromatography (60–120 mesh) using n–hexane/EtOAc (10:1 
v/v). It was recrystallized by dichloromethane/methanol (10:1 v/v), filtered and dried under 
vacuum to give a white crystal [V (A)] (Fig. 13) (1.2 g, 66.67% yield).  Melting point 172°C. 
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1H NMR (DMSO–d6) δ: 1.04 (s, 3H, -CH3), δ: 1.11 to 1.46 (m, 10H, -C6H10-), δ: 1.92 (s, 2H, 
-CH2-), δ: 3.10 (s, 1H, -OH). MS (ESI) m/z (M+H)+ 128.7.  
 
                                  
 
                                                                                                                          





Fig. 13 Synthesis of CSN. (A) Iodine, sodium borohydride, anhydrous THF, 0°C, RT; (B) 4-
hydroxybenzaldehyde, triphenylphosphine, diisopropyl azodicarboxylate, dry THF, 0°C, RT, 
18 h; (C) methanol, reflux, 2 h, 3-(triphenylphosphoranylidene)pyrrolidine-2,5-dione; (D) 




























Fig. 14 13C NMR interpretation of (A) (3Z)-3-{4-[(1 methylcyclohexyl)methoxy] 

















2.6.2 Synthesis of 4-[(1-methylcyclohexyl)methoxy]benzaldehyde [V (B)] 
  
4-Hydroxybenzaldehyde (1.14 g, 9.37 mmol) and triphenylphosphine (3.07 g, 11.7 
mmol) were added to a solution of (1-methylcyclohexyl)methanol (1 g, 0.781 mmol) in dry 
THF at 0°C. Diisopropyl azodicarboxylate (2.30 mL, 11.71 mmol) was added dropwise to the 
mixture over 15 min at 0°C. It was stirred for 18 h at RT. THF was removed under reduced 
pressure and EtOAc (100 mL) was added to it. The EtOAc layer was washed with 1N sodium 
hydroxide (20 mL), water (25 mL) and brine (20 mL). Then the organic layer was dried by 
anhydrous sodium sulfate and concentrated. The product was purified by silica gel column 
chromatography (60-120 mesh) using n-hexane/EtOAc (12:1 v/v) to give a yellow liquid [V 
(B)] (Fig. 13) (0.5 g, 24.21% yield).  1H NMR (DMSO–d6) δ: 1.04 (s, 3H, -CH3), δ: 1.16 to 
1.44  (m, 10H, -C6H10-), 2.12 (m, 2H, –CH2O-), δ: 7.36 (d, 2H, J=6 Hz, -C6H4-), δ: 7.99 (d, 
2H, J=6 Hz, -C6H4-), δ: 10.01 (s, 1H, -CHO). MS (ESI) m/z (M+H)+ 233.1.  
 
2.6.3 Synthesis of (3Z)-3-{4-[(1-methylcyclohexyl)methoxy]benzylidene}pyrrolidine-2,5-
dione [V (C)] 
 
A mixture of 3-(triphenylphosphoranylidene)pyrrolidine-2,5-dione (250 mg, 0.69 
mmol), 4-[(1-methylcyclohexyl)methoxy]benzaldehyde (160 mg, 0.69 mmol) and methanol 
(20 mL) was heated under reflux for 1.5 h and then cooled at RT. The reaction mixture was 
kept at 4°C overnight to promote the crystal formation. The resulting crystal was filtered, 
washed with methanol (20 mL) and dried under vacuum at 40°C to give a white solid [V (C)] 
(Fig. 13) (0.31 g, 91% yield). Melting point 181°C . 1H NMR (DMSO-d6) δ: 0.935 (m, 3H, -
CH3), 1.45 (m, 2H, -C6H10-), 1.70 (m, 2H, -C6H10-), 2.08 (m. 6H, -C6H10-), 3.60 (s. 2H, -
OCH2-), 4.02 (s, 2H, -CH2-), 7.01 (d, 2H, J=6 Hz, -C6H4-), 7.33 (s, 1H, –CH=), 7.55 (d, 2H, 
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J=9 Hz, -C6H4-), 11.33 (s, 1H, >NH). 13C NMR (DMSO-d6) 14.70, 19.73, 31.67, 35.80, 
39.75, 68.43, 115.97, 124.98, 127.69, 132.49, 133.08, 160.96, 173.17, 176.68 (Fig. 14A). MS 
(ESI) m/z (M+H)+ 314.2. 
 
2.6.4 Synthesis of  (R,S)-3-{4-[(1-methylcyclohexyl)methoxy]benzyl}pyrrolidine-2,5-dione [V 
(D)]  
  
A solution of (3Z)-3-{4-[(1-methylcyclohexyl)methoxy]benzylidene}pyrrolidine-2,5-
dione (100 mg, 0.31 mmol) in ethanol was taken in a parr bottle and 50 mg of Pd/C (10%) 
was added to it.  The compound was hydrogenated under hydrogen atmosphere (pressure 40 
psi) at RT for 8 h. The mixture was filtered using celite and concentrated by evaporation 
under reduced pressure to give a white solid [V (D)] (Fig. 13) (0.98 g, 98% yield, 99.8% 
purity). Melting point 142°C. 1H NMR (DMSO-d6) δ: 1.25 (s, 3H, -CH3), 1.52-156 (m, 2H, -
CH2-), 1.70-1.73 (m, 2H, -CH2-),  1.78-1.85 (m, 2H, -CH2-), 2.45-2.50 (m, 2H, -CH2-), 2.66-
2.71 (m, 2H, -CH2-), 2.86-2.92 (m, 2H, -CH2-), 2.99 -3.02 (m, 2H, -CH2-), 3.05 (s, 2H, -CH2-
), 3.32-3.39 (m, 1H, -CH<), 6.84 (d, 2H, J=6 Hz, -C6H4-), 7.08 (d, 2H, J=6 Hz, -C6H4-). 13C 
NMR (CDCl3) 14.70, 19.20, 31.27, 34.24, 35.30, 42.85, 67.67, 114.80, 129.99, 158.25, 
176.15, 179.15 (Fig. 14B). MS (ESI) m/z (M+H)+ 316.1. 
  
2.7 Discussion  
 
 In our present synthesis, we followed the same synthetic procedures for PRD 
analogues like TZD durg synthesis (page 21) except the last step. For the last step, PRD ring 
was converted to 3-(triphenylphosphoranylidene)pyrrolidine-2,5-dione first and this 
intermediate again reacted with corresponding aldehyde to get desired product .  
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A new chiral centre had been generated during synthesis for PRD analogues. The 
separation of compound from the racemic mixture was beyond our limit. We demonstrated 
that PRD analogues were racemic mixtrure (R,S) which were finally used for biological 
screening. The PRD analogues were successfully synthesized and characterized using NMR 
and MS. In the next chapter, RM profiling of the TZD drugs and the PRD analogues using 



























 Toxicity induced via metabolic activation is being increasingly screened during the 
drug discovery process in recent years. A variety of analytical methods were developed and 
employed for the profiling and characterization of RMs. Screening of RM-protein covalent 
adducts using HLM and liver cells from animals and humans is commonly used for the  
determination of RMs of drug candidates. Specifically, numerous methods have been 
developed to detect reactive RM-GSH adducts in vitro. The early LC/MS/MS method 
employed the neutral loss (NL) experiment (129 amu) to screen for the RM-GSH adducts 
(Dieckhaus et al., 2005) where the fragment of mass 129 corresponds to the polyglutamic 
acid moiety of GSH. The structure of each screened RM-GSH adduct can be further 
elucidated using product ion scan (PIS) experiment (Dieckhaus et al., 2005). In some cases,   
the effectiveness of the NL scanning experiment varies among different classes of RM-GSH 
adducts because the NL fragmentation patterns are compound-dependent (Dieckhaus et al., 
2005). To improve the sensitivity of the RM-GSH adduct screening by NL scan, stable-
isotope labelled GSH was explored as the trapping agent (Mutlib et al., 2005). Alternatively, 
multiple reaction monitoring (MRM) could be utilized to screen the transition of RM-GSH 
adduct from the protonated ion (parent ion, [M+H]+) to the corresponding product ion [MH–
129]+ (Soglia et al., 2004). In addition, a precursor ion scan experiment at m/z 272 in the   
ESI– mode had been employed to detect the RM-GSH adducts in biological samples 
(Christine et al. 2005). More recently, new MS techniques such as QTRAP MS (Joanna et al., 
2007; Li et al., 2009), orbitrap or fourier transform ion cyclotron resonance MS (Mingshe et 
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al., 2007) and new trapping agents such as γ-glutamylcysteine (Zhengyin et al., 2007), dansyl 
GSH (Jinping et al., 2009), quaternary ammonium GSH (Sogila et al., 2006) were used for 
the detection of RMs in biological samples in vitro. 
 In my project, NL scan at 129 amu and PIS experiments were performed for the 
profiling of RM-GSH adducts generated from the biotransformation of TZD antidiabetic 
drugs and their PRD analogues.  
    
3.2 Materials  
 
 GSH, potassium monohydrogen phosphate, potassium dihydrogen phosphate, bovine 
serum albumin, 0.5% trypsin-ethylenediaminetetraacetic acid solution (trypsin-EDTA), 
phosphate buffer saline and fetal bovine serum were purchased form Sigma-Aldrich (Saint 
Louis, MO, USA). HLM and nicotinamide adenine-di-neucleotide phosphate hydrogen 
(NADPH) regenerating system (solutions A and B), fibronectin and collagen were purchased 
from BD Biosciences (Woburn, MA, USA). TGZ, PGZ, RGZ and CGZ were purchased from 
Cayman Chemical Company (Ann Arbor, MI, USA). Bronchial epithelial cell basal medium 
(BEBM) provided with supplements (bronchial epithelial cell growth medium, BEGM 
BulletKit, CC-3170) was purchased from Cambrex Corporation (Rutherford, NJ, USA). 
THLE-2 cell line was purchased from ATCC (Manassas, VA, USA). All other reagents and 




3.3.1 HLM incubation for RM profiling  
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 50 mM stock solutions of all the test compounds (both the TZD and PRD analogues) 
were prepared individually in DMSO and diluted to a 5 mM working solution using 
methanol. For each compound, triplicate incubations (n = 3) were performed at 37°C in 300 
µL of 50 mM of potassium phosphate buffer (both potassium monohydrogen phosphate and 
potassium dihydrogen phosphate,) containing 2 mg/mL microsomal proteins and NADPH 
regenerating system. After 5 min pre-incubation, the reaction was initiated by the addition of 
30 µL of 50 mM GSH and 3 µL of the working solution of the substrate. The final reaction 
mixture contained 50 µM of substrate, 1.55 mM NADP+, 3.3 mM glucose-6-phosphate, 3.3 
mM magnesium chloride, 0.4 U/mL glucose-6-phosphate dehydrogenase, 0.05 mM sodium 
citrate and 5 mM of GSH. The final organic solvent concentration was 0.2% v/v. At 0 and 60 
min, 120 and 180 µL of the incubation mixture was quenched, respectively, with two 
volumes of cold ACN. These samples were centrifuged at 13,000 rpm for 10 min at 20°C. 
The supernatant was removed and evaporated to dryness at 35°C for 2 h under gentle flow of 
nitrogen gas using the Turbovap LV (Caliper Life Science, Hopkinton, MA, USA). The dried 
samples were reconstituted with 30 µL of ACN/water (50:50, v/v), vortex-mixed and 
centrifuged at 13,000 rpm for 2 min at 4°C. 3 µL of the supernatant was subjected to 
UPLC/MS/MS analysis. Negative control experiments were also performed in the absence of 
GSH, NADPH regenerating system or the substrate. 
 
3.3.2 THLE-2 cell culture 
 
 THLE-2 cells were cultured in plates pre-coated with collagen I (2.9 mg/mL), 
fibronectin (1 mg/mL) and bovine serum albumin (1 mg/mL) in BEBM according to ATCC 
guidelines.  For all cell-based experiments, THLE-2 cells were maintained in the logarithmic 
growth phase in BEBM supplemented with 10% fetal bovine serum and BEGM BulletKit in 
45 
 
humidified air with 5% CO2 at 37°C. Supplemented BEBM was termed as BEGM 
subsequently.  
 
3.3.3 THLE-2 incubation for RM profiling 
 
 THLE–2 cells were seeded into a 6–well plate (1.0×107 cells per well). 100 µM of 
each substrate was added to the cells and the mixture was incubated in a humidified condition 
(95% air/5% CO2) at 37°C. The final concentration of each test compound and organic 
solvent were 50 µM and 0.3% v/v, respectively. After 24 h (t24), the reaction was terminated 
by addition of 2 mL of ice cold ACN/water (50:50 v/v). Initial time point samples (t0) were 
prepared by terminating the reaction immediately after adding the test compound to the 
THLE-2 cells with the same quenching solvent. These samples were centrifuged at 13,000 
rpm at 4°C for 10 min and the supernatants were removed and evaporated to dryness at 35°C 
for 8 h under gentle flow of nitrogen gas using the Turbovap LV. They were each 
reconstituted with 50 µL of ACN/water (50:50 v/v), vortex-mixed and centrifuged for 13,000 
rpm at 4°C for 2 min. 5 µL of the supernatant was subjected to UPLC/MS/MS analysis. 
Negative control experiments were also performed in the absence of THLE-2 cells or the 
substrates.   
 
3.4 LC/MS/MS conditions 
 
The LC/MS/MS system comprised an ACQUITY UPLC system (Waters, Milford, 
MA, USA) interfaced with a hybrid QTRAP MS equipped with TurboIonSpray ESI source 
(3200 QTRAP, Applied Biosystems, Foster City, CA, USA). The UPLC and QTRAP MS 
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systems were both controlled by the Analyst 1.4.2 software (Applied Biosystems). The 
column and autosampler temperatures were maintained at 60 and 4°C, respectively. 
For the profiling of the RM-GSH adducts in HLM and THLE–2 cells, 
chromatographic separations were performed using an ACQUITY UPLC BEH C18 1.7 µm 
100 × 2.1 mm i.d. column (Waters). The flow rate was 0.5 mL/min and the mobile phases 
consisted of solvent A (0.1% formic acid in water) and solvent B (0.1% formic acid in ACN). 
The elution conditions were: linear gradient of 5 to 95% solvent B (0 – 9.50 min), isocratic at 
95% solvent B (9.50 – 10.50 min) and then isocratic at 5% solvent B (10.50 – 12.00 min). 
ESI+ mode was employed throughout the experiments. NL scan experiment at m/z 129 and 
PIS were performed to profile the RM-GSH conjugates. The optimized MS conditions are 
summarized in Table 2.  
 
Parameters Values 
Curtain gas, psi  25.0 
Ion spray voltage, V 4500.0 
CAD gas Medium 
Gas 1, psi 40.0 
Gas 2, psi 45.0 
Interface heater On 
Temperature, °C 550.0 
Declustering potential, V 80.0 
Entrance potential, V 10.0 
Collision cell entrance potential,V 25.0 
Collision energy, V 4.0 
Collision cell exit potential, V 1.0 
 
Table 2 Optimized MS parameters for the detection of RM-GSH adducts. 
3.5 Results 
3.5.1 RM profiling of TGZ and TSN  
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 LC/MS/MS analysis of TGZ incubated with HLM and THLE-2 cells revealed the 
presence of four RM-GSH adducts using NL scan of 129 amu. A representative RM-GSH 
adduct (RM1, [M+H]+ ion at m/z 722, retention time 4.78 min) was absent in “0 min TGZ-
HLM-GSH” and “0 h TGZ-THLE-2” samples but present in “60 min TGZ-HLM-GSH” and 
“24 h TGZ-THLE-2” incubations, respectively (Fig. 15C). RM1 was fragmented using PIS 
experiment and yielded product ions at m/z 647 [MH-75]+ and m/z 593 [MH-129]+ which 
shared characteristic fragmentation pattern of GSH-adducted conjugates. The PIS spectrum 
also contained an intense ion at m/z 416 [MH-306]+ that was derived via the retro-Michael 
cleavage of the RM-GSH adduct (Kassahun et al., 1994). Collectively, these characteristic 
fragmentation patterns supported that the RM1 was formed in vitro. In summary, RM1 is a 
RM-GSH adduct of TGZ where the disulfide bond formation occurred between the TZD 
ring-opened oxidized TGZ and sulfur moiety of GSH.   
 As shown in Fig. 15D, our experiments exhibited another RM-GSH adduct (RM2, 
[M+H]+ ion at m/z 747, retention time 4.45 min) when the “60 min TGZ-HLM-GSH” and 
“24 h TGZ-THLE-2” incubations were analyzed. As expected, this peak was absent in the 
corresponding “0 min TGZ-HLM-GSH”, “0 h TGZ-THLE-2” and negative control samples. 
RM2 underwent fragmentation using PIS experiment and yielded product ions at m/z 672 
[MH-75]+ and m/z 618 [MH-129]+. Interestingly, the PIS spectrum also contained an intense 
peak at m/z 308 [GSH2]+. Collectively, the characteristic fragmentation patterns indicated 
clearly the formation of RM2 in vitro. RM2 is a RM-GSH adduct of TGZ where the 
conjugation with GSH occurred at the C-5 position of TZD ring.Similar observations were 
made for RM3 ([M+H]+ ion at m/z 737, retention time 4.10 min) and RM4 ([M+H]+ ion at 
m/z 781, retention time 3.20 min).  RM3 yielded product ions at m/z 662 [MH-75]+ and m/z 











Fig. 15 NL scan at 129 amu of (A) 24 h TGZ-THLE-2 sample and (B) 60 min TGZ-HLM-
GSH sample. PIS of (C) RM1, m/z 722. 
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m/z 706 [MH-75]+ and m/z 652 [MH-129]+ (Fig. 15F). It is worthwhile to note that RM4 was 
found only in HLM but not in THLE-2 incubation. 
 Among the identified RM-GSH adducts in our LC/MS/MS experiment, RM1 is the 
oxidized product of TZD ring which is similar to oxidized product of M1 of TGZ (Kassahun 
et al, 2001). The molecular weight of RM1 (721 Da) is one mass unit higher than M1. RM1 
conjugate is related to carboxylic acid derivative of M1, formed by hydrolysis of the primary 
amide of the latter. RM2 is the direct adduct between C–5 position of TGZ ring and GSH (He 
et al. 2004). RM3 and RM4 are related to M4 and M2 of TGZ, respectively (Kassahun et al, 
2001). RM3 is related to direct adduct between quinoid TGZ and GSH while RM4 is the 
indirect adduct between S-hydroxyled TGZ and GSH.  
  Importantly, no RM was detected when TSN was incubated with HLM and THLE-2 
incubations. While it was possible for TSN to also form quinoid metabolite, we did not detect 
such metabolite in our experiment. This adverts to the possibility that PRD moiety, unlike 
TZD, is less prone to ring opening and attack by nucleophilic GSH. This observation 
suggested that the sulfur atom of the TZD ring of TGZ is responsible for the formation of 
RMs either directly or indirectly. TGZ had been shown to act as an inducer of CYP3A4 
enzymes in human hepatocytes which played an important role in metabolic activation of this 
drug (Ramachandran et al., 1999). Due to the enhanced metabolic activation of TGZ by 
CYP3A4, more reactive intermediates might be generated in the liver. This had been 
suggested to be a potential cause of TGZ inducing hepatotoxicity.  
 
3.5.2 RM profiling of PGZ and PSN 
 
Using NL scan of 129 amu, LC/MS/MS analysis of PGZ incubated with HLM and 
THLE-2 cells incubations revealed the presence of two RM-GSH adducts. A representative 
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RM-GSH adduct (RM5, [M+H]+ ion at m/z 636, retention time 2.43 min) was absent in “0 
min PGZ-HLM-GSH” sample but present in “60 min PGZ-HLM-GSH” incubation (Fig. 
16C). RM5 was also absent in “24 h PGZ-THLE-2” incubation. RM5 was fragmented using 
PIS experiment and yielded product ions at m/z 507 [MH-129]+ which shared characteristic 
fragmentation pattern of GSH-adducted conjugates. The PIS spectrum also contained an 
intense ion at m/z 331 [MH-306]+ that was derived via the retro-Michael cleavage of the RM-
GSH adduct (Kassahun et al., 1994). Collectively, these characteristic fragmentation patterns 
supported that RM5 was formed in vitro. In summary, RM5 is a RM-GSH adduct of PGZ 
where the disulfide bond formation occurred between the TZD ring-opened PGZ and sulfur 
moiety of GSH.  
As shown in Fig. 16D, another RM-GSH adduct (RM6, [M+H]+ ion at m/z 637, 
retention time 2.13 min) was determined when the “60 min PGZ-HLM-GSH” and “24 h 
PGZ-THLE-2” incubations were screened. As expected, the same peak was absent in the 
corresponding “0 min PGZ-HLM-GSH” and “0 h PGZ-THLE-2” incubations and negative 
control samples. RM6 underwent fragmentation using PIS experiment and yielded product 
ions at m/z 509 [MH-129]+. Collectively, the characteristic fragmentation patterns indicated 
clearly the formation of RM6 in vitro. RM6 was the oxidized product of RM5 where the 
amide moiety of RM5 was further oxidised to the corresponding carboxyl moiety in the 
incubation mixture. 
These two identified RM-GSH adducts (RM5, in HLM and RM6, in both HLM and 
THLE-2 incubations) were consistent with previous published adducts of PGZ (Baughman et 
al., 2005).  
No GSH adduct was detected when the same experiments were performed on PSN 













Fig. 16 NL scan of at m/z 129 amu of (A) 60 min PGZ-HLM-GSH sample and (B) 24 h PGZ-
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Fig. 16 (continue) PIS of (D) RM6, m/z 637. 
 
 
3.5.3 RM profiling of RGZ and RSN  
 
LC/MS/MS analysis of RGZ incubated with HLM and THLE-2 cells incubations 
revealed the presence of two RM-GSH adducts using NL scan of 129 amu. A representative 
RM-GSH adduct (RM7, [M+H]+ ion at m/z 637, retention time 2.06 min) was absent in “0 
min RGZ-HLM-GSH” and “0 h RGZ-THLE-2”samples but present in both “60 min RGZ-
HLM-GSH”  and “24 h RGZ- THLE-2” incubations (Fig. 17C). RM7 was fragmented using 
PIS experiment and yielded product ions at m/z 562 [MH-75]+ and m/z 508 [MH-129]+ which 
shared characteristic fragmentation pattern of GSH-adducted conjugates. Collectively, these 
characteristic fragmentation patterns supported that the RM7 was formed in vitro. In 
summary, RM7 is a RM-GSH adduct of RGZ where the disulfide bond formation occurred 
between the TZD ring-opened oxidized RGZ and sulfur moiety of GSH.  
As shown in Fig. 17D, our experiment yielded another RM-GSH adduct (RM8, 
[M+H]+ ion at m/z 638, retention time 1.73 min) when the “60 min RGZ-HLM-GSH” and 






















m/z 637 [MH-129]+ = 508 
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corresponding “0 min RGZ-HLM-GSH”, “0 h RGZ-THLE-2” and negative control samples. 
RM8 underwent fragmentation using PIS experiment and yielded product ions at m/z 563 
[MH-75]+ and m/z 509 [MH-129]+. Collectively, the characteristic fragmentation patterns 
indicated clearly the formation of RM8 in vitro. RM8 is a RM-GSH adduct of RM7 where 
the amide moiety of RM7 was oxidised to the corresponding carboxyl moiety in the 
incubation mixture. 
Our identified RM-GSH adducts (RM7 and RM8, in both HLM and THLE-2) were 
similar to previous published adducts of RGZ (Alvarez-Sánchez et al., 2006) confirming the 
reliability of our assay.  
No GSH adduct was detected when the same experiments were performed on RSN 




Fig. 17 NL scan of at m/z 129 amu of (A) 60 min RGZ-HLM-GSH and (B) 24 h RGZ-THLE-
2 sample.  
(A) 
(B) 
RM7, 2.06 min, m/z 637 
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Fig. 17 (continue) PIS of (C) RM7, m/z 637 and (D) RM8, m/z 638. 
 
 
3.5.4 RMs profiling using CGZ and CSN 
  
 No RM-GSH adduct was detected when the RM-GSH adduct screening experiments 
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3.6 Discussion  
 
 TGZ was withdrawn from market in 2000 due to its idiosyncratic liver toxicity 
(Chojkier, 2005) but the mechanism of toxicity remains unknown to clinicians. It is necessary 
to highlight that although many mechanisms had been proposed (Smith, 2003), the exact 
mechanism of toxicity remains elusive. Many unanswered questions remain for TGZ–
induced toxicity and we want to ascertain the contribution of the sulfur moiety to the toxicity 
of TGZ. It is also necessary to investigate the role of sulfur moiety of TZD ring of other TZD 
antidiabetic drugs (RGZ, PGZ, and CGZ) in inducing hepatotoxicity. Therefore, we aimed to 
first screen and characterize the electrophilic RM generated by the TZD drugs and their 
analogues.   
 In this chapter, we used GSH to trap reactive electrophilic intermediates and 
identified RM-GSH adducts in HLM and THLE-2 cells. Consistently, we observed TZD-
dependent bioactivation occurred for the TZD drugs in both enzymatic and cellular 
incubations using LC/MS/MS experiments. Our study revealed that both RGZ and PGZ were 
prone to form reactive intermediates, suggesting that these two compounds might be liable 
for toxicity in humans. This is consistent with the reports on clinical toxicity cases related to 
these two drugs. Unlike RGZ and PGZ, TGZ generated a quinone-related RM-GSH adduct, 
RM3, as a predominant product detected in both HLM and THLE-2 cells. The formation of 
this unqiue quinone reactive intermediate might account for potential oxidative stress-induced 
toxicity associated with TGZ in humans (Smith 2003). We confirmed the generation of RMs 
by the TZD drugs, however, a pertinent question arose if these RMs account for toxicity in 
humans?   
 To get the answer to the above question, we prepared the PRD analogues. When the 
PRD analogues were incubated with both HLM and THLE-2 cells, no clear RM-GSH adduct 
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was detected. One possible reason was that the PRD moiety, unlike TZD, was less prone to 
ring opening and attack by nucleophilic GSH. This observation suggests that the sulfur atom 
of the TZD ring is responsible for the formation of RMs either directly or indirectly. When 
the sulfur moiety of TZD ring was substituted by the methylene moiety of the PRD ring, we 
found that this structural modification circumvented RM formation. Therefore, such 
structural modification may become an important strategy to reduce the toxicity of the TZD 
class of antidiabetic drugs.  
 RM4 and RM5 were absent in “24 h TGZ-THLE-2” and“24 h PGZ-THLE-2” 
incubations. THLE-2 cells contain more CYP3A4 and less CYP2C8 enzymes (Andrea et al., 
1993). Both TGZ and PGZ are mainly metabolized by both CYP3A4 and CYP2C8. RM4 and 
RM5 were not produced during incubation due to absence of CYP2C8 enzymes in THLE-2 
cells.  
 We observed that TZD antidiabetic drugs formed TZD-ring opened oxidized reactive 
intermediates during both HLM and THLE-2 incubations. The questions arose whether these 
TZD drugs may produce any oxidative stress in THLE-2 cells. Therefore, to link the 
formation of RMs to the onset of toxicity, we further performed cell cytotoxicity assays using 
THLE-2 cells. In the next chapter, the cytotoxicity assays of the TZD and PRD analogues 













4.1 Introduction  
 
Chapter four presents and discusses the cytotoxicity assays of TZD and PRD 
analogues using metabolically active THLE-2 cells. To make correlation between RMs 
formation and toxicity, we performed MTT cell viability, GSH and protein carbonyl (PC) 
assays. GSH and PC assays were performed to examine the mechanism of toxicity of TZD 
antidiabetic drugs.  
 MTT cell viability assay is used preliminarily to detect the cytotoxicity of compounds 
in vitro. Several methods had been used for the determination of cell viability. Among them, 
trypan blue staining is a simple way to evaluate cell membrane integrity and assume cell 
proliferation or death. However, the method is not sensitive and cannot be used for high 
throughput screening. Therefore, researchers perform the cell viability using trypan blue first 
and then using MTT. Yellow MTT is reduced to purple formazan in the mitochondria of 
living cells. The absorbance of this colour solution can be quantitated by measuring light at a 
certain wavelength (usually between 500 and 600 nm) via a spectrophotometer. This 
reduction takes place when mitochondrial reductase enzymes are active and can be directly 
related to the number of viable (living) cells. When the amount of purple formazan produced 
by cells treated with an agent is compared with the amount of formazan produced by 
untreated control cells, the effectiveness of the agent in causing the death of cells can be 
derived from the dose-response curve. An increase in the cell number results in an increase in 
the formation of MTT formazan and a corresponding increase in absorbance. The MTT 
method has a few limitations. The assay depends on physiological state of the cells and 
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variance in mitochondrial dehydrogenase activity in different cell types (Bigl et al., 2007). 
Nevertheless, the MTT assay is useful for the measurement of cell growth in response to 
mutagens, antigenic stimuli, growth factors and cytotoxicity studies. For MTT assay, 









 To link RM formation to the mechanism of toxicity, a question arose whether the 
TZD antidiabetic drugs exert any direct effect on endogenous GSH depletion. Preliminary 
investigation revealed that TGZ-induced hepatotoxicity might be due to the formation of 
oxidized TZD ring-opened RMs. To confirm this observation, it is necessary to confirm 
whether the TZD drugs produce oxidative stress in normal human hepatocytes. In the thesis, 
we performed GSH depletion assay on all TZD drugs and their analogues using THLE-2 
cells.  GSH is a tripeptide comprising of L-cysteine, L-glutamic acid and glycine. It is an 
antioxidant which protects cells from reactive oxygen species (ROS) such as free radicals and 
peroxides (Prompela et al., 2003). GSH acts as nucleophile which binds to poisonous 
electrophile in our body. Thiol groups are kept in reduced state at a concentration of 
approximately ~5 mM in animal cells. GSH is converted to its oxidized form glutathione 
disulfide (GSSG) during oxidative stress. In fact, the ratio of GSH to GSSG within cells is 
used scientifically as a measurement of cellular toxicity (Pastore et al., 2003). The depletion 
of GSH has dual implications in the biochemical system. The depletion of GSH is either 
effected via adduct formation to RM-GSH conjugates or via oxidation to GSSG suggesting 
oxidative stress.  
  While several methods are available for the determination GSH in biological samples, 
oxidation of GSH remains a major problem during sample preparation. Therefore, the 
blocking of thiol group using various agents such as N-ethylmaleimide (NEM), iodoacetic 
60 
 
acid and 2-vinyl pyridine has been explored to prevent GSH oxidation (Roman et al., 2007). 
A variety of HPLC methods with ultraviolet (UV) detection had been developed for the 
detection of GSH in the biological samples (Farris and Reed, 1987; Katrusiak et al., 2001). 
The main drawback of HPLC-UV method is its poor limit of detection. While HPLC with 
fluorescence detection is more sensitive than the HPLC-UV method, it requires sample 
derivatization and is relatively more tedious (Cereser et al., 2001). Recently, LC/MS/MS had 
been developed for the determination of GSH or GSH conjugates from biological systems 
(Ranieri et al., 2006). In our study, we performed GSH assay using LC/MS/MS (ESI+ mode 
and MRM transition) with NEM as derivatizing agent. The decreased GSH synthesis may be 
a possibility causing GSH depletion in our LC/MS/MS experiments.     
 The implication of GSH depletion is related to both oxidative stress and its binding to 
RM. Therefore, a more specific assay for oxidative stress may be necessary to help relate or 
differentiate between the two possibilities. Therefore, PC assay was performed to elucidate 
the mechanism of toxicity. Reactive oxygen species (ROS) are formed during normal 
metabolism and in various pathological conditions. They cause cellular damage by the 
oxidation of amino acid residues on proteins and form PC. PC is the most widely used marker 
of oxidative modification of proteins. There are several methodologies available for the 
quantitation of PC in the biological system. Among them, 2,4-dinitrophenylhydrazine is the 
common reagent for the determination of PC which forms the corresponding hydrazone in the 
incubation mixture and can be analyzed spectrophotometrically (Levine et al., 1990; Chevion 
et al., 2000). In our study, we performed PC assay spectrophotometrically using 2,4-
dinitrophenylhydrazine as derivatizing reagent.     
 Before performing the MTT, GSH and PC assays, it was necessary to investigate the 
stability of each TZD and PRD analogues in BEGM to correlate the toxicity and oxidative 
stress end-points with the expected level of each parent compound. Hence, we first performed 
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stability studies of the TZD and PRD analogues at varying concentrations (1 and 50 µM) in 
BEGM at 37°C up to 72 h.   
 
4.2 Materials   
 
GSH, GSSG, MTT, trichloroacetic acid (TCA), NEM, guanidine hydrochloride, 2,4-
dinitrophenylhydrazine, trypan blue, tocopherol acetate (TA) were purchased form from 
Sigma-Aldrich (Saint Louis, MO, USA). Ethylenediaminetetraacetic acid disodium salt 
dihydrate (Na2EDTA•2H2O) with > 98% purity was obtained from Duchefa Biochemie B. V. 
(Haarlem, The Netherlands). All other reagents and chemicals used for the experiments were 
of analytical grade.  
 
4.3 Methods  
 
4.3.1 Stability studies of TZD and PRD analogues  
 
4.3.1.1BEGM incubation conditions 
 
 Stability studies of TZD and PRD analogues at 1.0 and 50.0 µM were performed 
using BEGM at 37ºC up to 72 h. At various time points (0, 24, 48 and 72 h), 1 mL methanol 
was added to 1 mL of the incubation mixture. Subsequently, each sample was centrifuged at 
13,000 rpm for 5 min and the supernatant was removed and evaporated to dryness at 40°C for 
8 to 10 h under a gentle flow of nitrogen gas using the Turbovap LV. Each dried residue was 
reconstituted with 50 µL of methanol, vortex-mixed and centrifuged at 13,000 rpm for 2 min. 
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5 µL of the supernatant was subjected to UPLC/MS/MS analysis. Triplicate analyses were 
performed at each time point.  
 
4.3.1.2 LC/MS/MS conditions 
 
 For the stability studies using LC/MS/MS, LC experimental setup was similar to that 
we used for the profiling of RM-GSH conjugates. MRM in ESI+ and ESI– mode were 
employed throughout the experiment for stability studies. The MS conditions are summarized 
in Tables 3 and 4 for TZD and PRD analogues, respectively. For stability studies, all 
chromatographic peak area integrations were performed using the Analyst Software v 1.4.2 
(Applied Biosystems) and analyzed using GraphPad Prism 4 (San Diego, CA, USA).   
MRM transitions were performed in ESI- mode at m/z 440.0→397.0, m/z 
356.0→313.0 and m/z 332.0→289.0 for TGZ, RGZ and CGZ, respectively. MRM transition 
was performed in ESI+ mode at m/z 357.0→134.0 for PGZ.  
 MRM transitions were performed in ESI+ mode at m/z 339.0→134.0, m/z 340.0 
→263.0 and m/z 316.0→106.0 for PSN, RSN and CSN, respectively while MRM transition 
was performed in ESI- mode at m/z 422.0→203.0 for TSN.  
 The common MS parameters for the TZD and PRD analogues were as follows: 
curtain gas (CUR); 10 psi, ion spray voltage; -4500 V, collision gas (CAD); medium, ion 
source gas (GS1); 40 psi, ion source gas (GS2); 45 psi, interface heater; On, temperature; 








 TGZ PGZ RGZ CGZ 
 
Declustering Potential, V -49.0 52.0 -50.0 -57.0 
 
Entrance potential, V -5.6 7.0 -3.0 -2.0 
 
Collision energy, V -30.0 40.0 -35.2 -29.0 
 
Collision cell exit potential, V -4.0 2.4 -3.0 -2.0 
 
 
Table 3 Optimized MS parameters for stability studies of the TZD analogues.  
 
Parameters Values 
 TSN PSN RSN CSN 
 
Declustering Potential, V -80.0 56.0 20.0 57.0 
 
Entrance potential, V -4.0 40.0 1.0 8.0 
 
Collision energy, V -42.0 38.0 35.0 32.5 
 
Collision cell exit potential, V -2.0 2.0 3.8 3.3 
 
 
Table 4 Optimized MS parameters for stability studies of the PRD analogues. 
 
4.3.2 MTT viability assay 
 
 MTT viability assay was performed as described previously (Marcsek et al., 2007). 
Briefly, THLE–2 cells were seeded into 96-well plate (1.0×104 cells per well). After 24 h, the 
medium was removed and 200 µL of varying concentrations of TZD and PRD analogues (1 
to 150 µM) in media was added to each well and the samples were incubated in a humidified 
condition 5% CO2 at 37°C. After 72 h, MTT solution (1 mg/mL, 50 µL) was added to each 
well and incubated for another 4 h. After which, the media and excess MTT were removed 
and 150 µL of DMSO was added. The absorbance at 570 nm was recorded using the Infinite 
M200 microplate reader controlled by Magellan and i-control softwares (Tecan Group Ltd., 
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Mannedorf, Switzerland). Samples containing media with and without cells were also 
analyzed and labelled as ‘control’ and ‘blank’, respectively. Another assay was performed by 
spiking 20 µM of TA (antioxidant) at varying concentrations of analytes (1–150 µM) in 
THLE-2 cells (Patrick et al., 2005). Independently, we performed the cytotoxicity assay of 
TA (1, 10, 50 and 100 µM concentrations) in THLE-2 cells in the absence of analytes. All the 
experiments were performed in triplicates. The final organic solvent concentration was 0.3% 
(v/v). Cell survival (% of control) was calculated relative to untreated control cells. Data were 
analyzed by GraphPad Prism 4 and represented as the mean ± S.D. of triplicate experiments 
to determine the EC50 of the respective compounds. Statistical differences were analyzed 
using one–way analysis of variance (one–way ANOVA) and paired T–test and P<0.05 
represented the statistically significant data.  
 
4.3.3 GSH depletion assay 
 
4.3.3.1 Preparation of calibration curve  
 
The details of our GSH assay using NEM as a derivatizing agent to prevent auto-
oxidation of GSH had been previously published (New and Chan, 2008). To prevent auto-
oxidation of GSH during sample preparation, a derivatizing solution (solution A) was 
prepared freshly by mixing NEM and Na2EDTA•2H2O in water/methanol (3:2 v/v) and 
adjusting the pH of the solution to 7.4 with solid sodium bicarbonate. The final 
concentrations of NEM and Na2EDTA•2H2O in solution A were 250 mM and 1.5 mg/mL, 
respectively. Under these conditions, the oxidation of GSH will be terminated by the 
formation of a stable GSH derivative, GSH-NEM.  
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50 mM stock solution of GSH was prepared freshly in water and its calibrated 
concentrations were prepared via serial dilutions of this stock solution using water. 200 µL 
each of the calibrants was added to 50 µL of solution A in a 1.5 mL microcentrifuge tube and 
vortex-mixed at high speed for 20 s. Then 50 µL of TCA was added and the mixture was 
centrifuged at 13,000 rpm for 5 min at 4°C. 300 µL of the supernatant was collected into a 
clean tube and subjected to LLE using 2 mL of dichloromethane. The mixture was vortexed 
at high speed for 1 min and subsequently centrifuged at 13,000 rpm for 8 min at 4°C. 300 µL 
of the supernatant was collected into a clean tube and evaporated to dryness for 2 h at 35°C 
under nitrogen using the Turbovap LV. The residue was reconstituted with 100 µL of water, 
vortex-mixed and centrifuged at 13,000 rpm for 5 min. 3 µL of supernatant was injected for 
UPLC/MS/MS analysis. The concentrations of the GSH-NEM calibrants were 0.001, 0.01, 
0.05, 0.1, 0.5, 1.0 and 10.0 µM. Quality control (QC) samples were also prepared at 
concentrations of 0.003, 0.05 and 8.0 µM, representing low, medium and high QC samples 
(LQC, MQC and HQC), respectively. Triplicate samples were prepared at each 
concentration.  
 
4.3.3.2 GSH depletion assay using THLE-2 cells  
  
 THLE-2 cells were seeded into 24-well plate (2.0×104 cells/well). After 24 h, 1 mL of 
varying concentrations of TZD and PRD analogues in BEGM (1, 10, 25, 50, 75, 100, 125 and 
150 µM) was added to each well and incubated in a humidified condition 5% CO2 at 37°C. 
After 72 h incubation, cells were washed with phosphate buffer saline and trypsinized using 
0.05% trypsin-EDTA. Subsequently, the excess trypsin was inactivated with BEGM. The 
suspended cells were then transferred into clean tubes, centrifuged at 13,000 rpm for 2 min 
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and the supernatant removed. After which, 200 µL of water was added to the cell samples 
and 50 µL of solution A (mixture of NEM [250 mM] and Na2EDTA•2H2O [1.5 mg/mL] in 
water/methanol [3:2], pH 7.4) was added to it. The mixture was vortex-mixed at high speed 
for 20 s. Then 50 µL of TCA (10%) was added and the mixture was centrifuged at 13,000 
rpm for 5 min at 4°C. The supernatant was transferred into clean tubes and subjected to NEM 
derivatization and extraction as previously published (New and Chan, 2008). Total protein 
content of cell suspension was measured at 72 h using the Pierce Micro BCATM 
(Bicinchoninic acid) Protein Assay Kit. 
 
4.3.3.3 LC/MS/MS conditions  
 
 In the measurement of GSH depletion assay, an ACQUITY UPLC HSS T3 1.8 µm 
100 × 2.1 mm i.d. column (Waters) was used to achieve chromatographic separation. The 
mobile phases and optimized elution conditions utilized were published previously (New and 
Chan, 2008) (Table 5). ESI+ mode and MRM were employed throughout the experiments. 
The MRM transition for GSH-NEM was m/z 433.0→304 and the MS conditions are 
summarized in Table 6. For GSH depletion assay, all chromatographic peak area integrations 
were performed using the Analyst Software v 1.4.2 and analyzed using GraphPad Prism 4. 
Statistical differences were analyzed using one-way ANOVA and paired T-test. P<0.05 








Time (min) % B Curve 
0.00 0.1 - 
2.00 2.0 9 
3.50 30.0 3 
3.51 95.0 6 
4.79 95.0 6 
4.80 0.1 6 
6.00 0.1 6 
 
Table 5 Optimized LC conditions for GSH depletion assay (New and Chan, 2008). 
 
Parameters Values 
Curtain gas, psi 15.0 
Ion spray voltage, V 5000.0 
CAD gas Medium 
Gas 1, psi 40.0 
Gas 2, psi 45.0 
Interface heater On 
Temperature, °C 500.0 
Declustering potential, V 29.55 
Entrance potential, V 5.43 
Collision cell entrance potential, V 15.00 
Collision energy, V 18.00 
Collision cell exit potential, V 2.00 
Scan time, ms 250 
 
Table 6 Optimized MS parameters for GSH depletion assay.  
 
 




 PC assay was performed as described previously (Reznick and Packer, 1994). In brief, 
THLE-2 cells were seeded at 5.0×104 cells/well into 6-well plate which was previously 
coated with the fibronectin-collagen medium. After 24 h, 2 mL of varying concentrations of 
TZD and PRD analogues in BEGM (1 to 50 µM) were added to each well and incubated at 
37°C in a humidified condition at 5% CO2. After 48 h, each medium was removed and the 
cells were washed with phosphate buffer saline.  The cells were removed from the surface of 
the plates using 0.05% trypsin-EDTA and the excess trypsin was deactivated by adding 
BEGM. Media containing cells were transferred into clean tubes and centrifuged at 13,000 
rpm for 2 min. The supernatant was removed, the cell pellet was reconstituted with 300 µL of 
water and vortexed for 1 min. 150 µL of cell suspension was aliquoted into a clean tube and 
precipitated using 500 µL of 10% TCA solution. The tubes were centrifuged subsequently at 
13,000 rpm for 2 min and the supernatant was removed. Each cell pellet was incubated with 
500 µL of 0.2% 2,4-dinitrophenylhydrazine for 1 h with constant vortexing at every 5 min 
interval. 50 µL of 100% TCA solution was added, vortexed and centrifuged at 13,000 rpm for 
5 min. All the supernatant was removed and the cell pellet was washed with 500 µL of 
ethanol: EtOAc (1:1 v/v) mixture three times. Finally, the cell pellet was dissolved in 600 µL 
of 6 M guanidine hydrochloride and 300 µL was transferred to a 96-well plate and 
absorbance was measured at 360 nm using the Infinite M200 microplate reader. The 
remaining 150 µL of cell suspension was used for measuring total protein content using the 
Pierce Micro BCATM (Bicinchoninic acid) Protein Assay Kit. PC content (µM) per µg of 
protein was calculated at varying concentration of the test compounds. All data were 
analyzed by GraphPad Prism 4. Statistical differences were analyzed using one-way ANOVA 
and paired T-test. P<0.05 represented statistical significance between groups. All the 




4.4 Results  
 
4.4.1 Stability studies  
 
 Stability studies of TZD antidiabetic drugs and synthesized PRD analogues were 
performed using BEGM at 37ºC up to 72 h. The results of stability studies are described 
below. The stability ranges were 100 ± 15% up to 72 h for the TZD and PRD analogues.     
 
4.4.1.1 Stability studies of TGZ and TSN  
 
 The retention time of TGZ and TSN were 6.44 (Fig. 18A) and 8.11 (Fig. 18B) min, 
respectively. Our stability study demonstrated that TGZ and TSN at both 1.0 and 50.0 µM 





Fig. 18 Representative LC/MS/MS chromatograms of (A) TGZ (6.44 min), (B) TSN (8.11 
min) in BEGM.  
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Fig. 19 Stability profiles of TSN at (A) 1 and (B) 50 µM, TGZ at (C) 1 and (D) 50 µM in 
BEGM at 37ºC up to 72 h (average±SD, n=3).  
 
 Our stability studies showed that TSN was stable at 1 µM (101.43%) (Fig. 19A) and 
50 µM (111.28%) (Fig. 19B) while TGZ was stable at 1 µM (101.67%) (Fig. 19C) and 50 
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4.4.1.2 Stability studies of PGZ and PSN  
 
 The retention time of PGZ and PSN were 3.13 (Fig. 20A) and 2.66 (Fig. 20B) min, 
respectively. Our stability study demonstrated that PGZ and PSN at both 1.0 and 50.0 µM 








Fig. 20 Representative LC/MS/MS chromatograms of (A) PGZ (3.13 min), (B) PSN (2.66 
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Fig. 21 Stability studies of PSN at (A) 1 and (B) 50 µM, PGZ at (C) 1 and (D) 50 µM in 
BEGM at 37ºC up to 72 h (average±SD, n=3).  
 
 
 Our stability studies showed that PSN was stable at 1 µM (108.26%) (Fig. 21A) and 
50 µM (94.53%) (Fig. 21B) while PGZ was stable at 1 µM (106.04%) (Fig. 21C) and 50 µM 
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4.4.1.3 Stability studies of RGZ and RSN  
 
 The retention time of RGZ and RSN were 2.59 (Fig. 22A) and 5.39 (Fig. 22B) min, 
respectively. Our stability study demonstrated that RGZ and RSN at both 1.0 and 50.0 µM 









Fig. 22 Representative LC/MS/MS chromatograms of (A) RGZ (2.59 min), (B) RSN (5.39 





































   
RSN 50 µM








































   
RGZ 50 µM






















Fig. 23 Stability studies of RSN at (A) 1 and (B) 50 µM, RGZ at (C) 1 and (D) 50 µM in 
BEGM at 37ºC up to 72 h. 
 
 
 Our stability studies showed that RSN was stable at 1 µM (97.26%) (Fig. 23A) and 50 
µM (99.65%) (Fig. 23B) while RGZ was stable at 1 µM (110.48%) (Fig. 23C) and 50 µM 
(105.61%) (Fig. 23D) up to 72 h incubation (average±SD, n=3).  
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4.4.1.4 Stability studies of CGZ and CSN  
 
The retention time of CGZ and CSN were 7.65 (Fig. 24A) and 7.31 (Fig. 24B) min, 
respectively. Our stability study demonstrated that CGZ and CSN at both 1.0 and 50.0 µM 







Fig. 24 Representative LC/MS/MS chromatograms of (A) CGZ (7.65 min) and (D) CSN 
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Fig. 25 Stability studies of CSN at (A) 1 and (B) 50 µM, CGZ at (C) 1 and (D) 50 µM in 
BEGM at 37ºC up to 72 h (average±SD, n=3). 
 
 
Our stability studies showed that CSN was stable at 1 µM (95.32%) (Fig. 25A), and 
50 µM (113.86%) (Fig. 25B) while CGZ was stable at 1 µM (106.49%) (Fig. 25C) and 50 
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4.4.2 MTT viability assay 
 
 MTT viability assays of the TZD and PRD analogues were performed using THLE-2 
cells. The final results regarding MTT assays are described below.  
 
4.4.2.1 MTT viability assay of TGZ and TSN  
 
THLE-2 cells were treated with TGZ and TSN at varying concentrations for 72 h. As 
shown in Fig. 26A, the cell viability of THLE–2 was decreased with increasing concentration 
of both compounds. Minimal toxicity was observed at 1 µM for both compounds and 
viability was similar up to 10 µM (90% cell viability).  However, the cytotoxic effect was 
more pronounced for TGZ than TSN from 25 µM, with viability reducing to 50% at 75 µM 
of TGZ. The calculated EC50 for TGZ and TSN were 41.12 ± 4.3 µM and 138.5 ± 7.3 µM, 
respectively. Statistical differences were demonstrated between control and test compounds 
(one-way ANOVA, P<0.05) and between TGZ and TSN (paired T–test, P<0.05) at and above 
25 and 50 µM concentration, respectively. Our results further demonstrated that TGZ was 
more toxic than TSN above 50 µM when TA (antioxidant) was co–incubated at 20 µM level 
(Fig. 26B). Statistical differences were observed between TGZ and TSN in terms of 
percentage cell viability at and above 100 µM (paired T–test, P<0.05). The viability of 
THLE–2 cells was not affected by the presence of TA up to a concentration of 100 µM (data 
not shown).  
 
4.4.2.2 MTT viability assay of PGZ and PSN 
 
THLE–2 cells were treated with PGZ and PSN at varying concentrations (1–150 µM) 







































Fig. 26 (A) Percentage MTT cell viabilities of THLE-2 cells at varying concentrations of 
TGZ and TSN. Statistical differences were demonstrated between control and test compounds 
(one-way ANOVA, P<0.05) and between TGZ and TSN (paired T-test, P<0.05) at and above 
25 and 50 µM concentration, respectively. (B) Percentage MTT cell viabilities of THLE-2 
cells at varying concentrations of TGZ and TSN co-incubated with 20 µM TA. Statistical 
differences were observed between TGZ and TSN in terms of percentage cell viability at and 














































































Fig. 27 (A) Percentage MTT cell viabilities of THLE-2 cells at varying concentrations of 
PGZ and PSN. Statistical differences were demonstrated between control and test compounds 
(one-way ANOVA, P<0.05) at and above 50 µM concentration. Statistical differences were 
also observed between PGZ and PSN (paired T–test, P<0.05) at 50, 75 and 100 µM. (B) 
Percentage MTT cell viabilities of THLE-2 cells at varying concentrations of PGZ and PSN 
co-incubated with 20 µM TA. Statistical differences were observed between PGZ and PSN in 
terms of percentage cell viability at 75, 100 and 125 µM (paired T-test, P<0.05). 
 
 
PGZ and PSN where an increase in dose of each test compound was associated with a 
consistent decline in cell viability. It was shown that when each compound was incubated 
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with THLE–2 cells, toxicity was observed from 10 µM with respect to control in both cases.  
However, the observed toxic effect of PGZ was greater than PSN after 10 µM. The THLE–2 
cell viability was 50% at 75 µM of PGZ and remained unchanged up to 150 µM. On the other 
hand, cell viability was 70% at 75 µM of PSN and remained 60 % at and above 100 µM of 
PSN. The calculated EC50 for PGZ and PSN were 77.12 ± 10.04 and 107.22 ± 20.51 µM, 
respectively. Statistical differences were demonstrated between control and test compounds 
(one–way ANOVA, P<0.05) at and above 50 µM concentration. Statistical differences were 
also observed between PGZ and PSN (paired T–test, P<0.05) at 50, 75 and 100 µM. To 
determine whether the increased cytotoxicity of PGZ was linked to oxidative stress, we co–
incubated both treatments with the antioxidant, TA. The results further demonstrated that 
PGZ was more toxic than PSN above 75 µM when the compounds were co–incubated with 
TA at 20 µM level (Fig. 27B). Statistical differences were observed between PGZ and PSN in 
terms of percentage cell viability at 75, 100, 125 µM (paired T–test, P<0.05). By comparing 
Fig. 27A and 27B, it was clear that PGZ produced less toxicity in the presence of TA as 
compared to PGZ alone. There were no significant differences observed between PSN alone 
and PSN co-incubation with TA up to 100 µM. This result might be due to the relatively 
lower oxidative stress effect caused by PSN in THLE-2 cells.   
 
4.4.2.3 MTT viability assay of RGZ and RSN 
 
 THLE-2 cells were treated with RGZ and RSN at various concentrations (1–150 µM) 
for 72 h. It was shown that the cell viabilities were decreased according to the increase of 
incubated concentrations of both compounds. Both compounds showed significant decrease 
in viability at and above 25 µM with respect to control whereas there was no significant 
statistical difference observed between them up to 150 µM (Fig. 28A). Statistical differences 
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were demonstrated between control and test compounds (one-way ANOVA, P<0.05) at and 
above 25 µM concentration. There were no significant differences observed when the 


































Fig. 28 (A) Percentage MTT cell viabilities of THLE-2 cells at varying concentrations of 
RGZ and RSN. Statistical differences were demonstrated between control and test 
compounds (one-way ANOVA, P<0.05) at and above 25 µM concentration. (B) Percentage 
MTT cell viabilities of THLE-2 cells at varying concentrations of RGZ and RSN co-






















































































Fig. 29 (A) Percentage MTT cell viabilities of THLE-2 cells at varying concentrations of 
CGZ and CSN. Statistical differences were demonstrated between control and test 
compounds (one-way ANOVA, P<0.05) at and above 25 µM concentration.  (B) Percentage 
MTT cell viabilities of THLE-2 cells at varying concentrations of CGZ and CSN co-
incubated with 20 µM TA.  
  
THLE-2 cells were treated with CGZ and CSN at various concentrations (1–150 µM) 
for 72 h. It was shown that the cell viabilities were decreased according to the increase of 
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incubated concentrations for both these compounds. Both compounds showed significant 
decrease in viability at and above 25 µM with respect to control whereas there was no 
significant statistical difference observed between them up to 150 µM (Fig. 29A). Statistical 
differences were demonstrated between control and test compounds (one-way ANOVA, 
P<0.05) at and above 25 µM concentration. There were no significant differences observed 
when the compounds were co–incubated with TA at 20 µM concentration (Fig. 29B).  
 
4.4.3 GSH depletion assay 
 
Determination of GSH-NEM was performed in THLE-2 cells after 72 h incubation 
with the TZD and PRD analogues at varying concentrations (1–150 µM). A linear regression 
performed over a range of 0.001 to 10 µM yielded a correlation coefficient (r2) of 0.9985 to 
0.9999. The accuracy of the assay was found to be within 80 to 108%. The percentage 
recoveries of the GSH-NEM complex in QC samples were 60 to 80%. The retention time for 
GSH-NEM complex was 3.13 min (Fig. 30). The GSH depletion capacities of TZD and PRD 
analogues are described below.     
 
4.4.3.1 GSH depletion assay of TGZ and TSN  
 
The GSH depletion (µM) per µg of protein was measured at varying concentrations of 
TGZ and TSN after 72 h. TGZ depleted more GSH than TSN after 50 µM. According to Fig. 
31, it was seen that TGZ depleted more GSH than TSN from 1 to 150 µM. The GSH-NEM 
concentration of 2.0×104 cells/well was ~ 9 to 2 µM per µg of protein in case of TGZ whereas 
GSH-NEM concentration was higher ~ 9 to 4 µM per µg of protein for TSN from 1 to 150 
µM concentrations. Statistical differences were demonstrated between control and test 
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compounds (one-way ANOVA, P<0.05) and between TGZ and TSN (paired T-test, P<0.05) 
at and above 25 and 75 µM, respectively. 
 
 
      
 
Fig. 30 Representative LC/MS/MS chromatogram of GSH-NEM complex (3.13 min). 
 
























Fig. 31 GSH depletion in THLE-2 cells at varying concentrations of TGZ and TSN. 
Statistical differences were demonstrated between control and test compounds (one-way 













4.4.3.2 GSH depletion assay of PGZ and PSN  
  
Determination of GSH-NEM adducts was performed in THLE-2 cells after 72 h 
incubation with PGZ and PSN (Fig. 32). PGZ depleted more GSH than PSN after 25 µM 
concentration. The total GSH-NEM concentration was ~ 7 to 1 µM per µg of protein for PGZ 
whereas it was ~ 7 to 2.5 µM per µg of protein for PSN from 1 to 150 µM. Statistical 
differences were demonstrated between control and test compounds (one-way ANOVA, 
P<0.05) at and above 25 µM. Statistical differences were also observed between PGZ and 
PSN (paired T-test, P<0.05) from 25 to 100 µM.   
 
 


























Fig. 32 GSH depletion in THLE-2 cells at varying concentrations of PGZ and PSN. 
Statistical differences were demonstrated between control and test compounds (one-way 
ANOVA, P<0.05) at and above 25 µM. Statistical differences were also observed between 






4.4.3.3 GSH depletion assay of RGZ and RSN 
  
Determination of GSH-NEM adducts was performed in THLE-2 cells after 72 h 
incubation with RGZ and RSN (Fig. 33). RGZ depleted more GSH than RSN at 
concentration greater than 25 µM. RSN showed no toxicity up to 100 µM with respect to 
control. The concentration of GSH-NEM was ~ 6 to 5 µM per µg of protein for RSN whereas 
its concentration was ~ 6 to 1.5 µM per µg of protein for RGZ from 1 to 150 µM. Statistical 
differences were demonstrated between control and test compounds (one-way ANOVA, 






























Fig. 33 GSH depletion in THLE-2 cells at varying concentrations of RGZ and RSN. 
Statistical differences were demonstrated between control and test compounds (one-way 
ANOVA, P<0.05) and between RGZ and RSN (paired T-test, P<0.05) at and above 100 and 






4.4.3.4 GSH depletion assay of CGZ and CSN  
 
The GSH depletion (µM) per µg of protein was measured at varying concentrations of 
CGZ and CSN after 72 h (Fig. 34). CGZ depleted more GSH than CSN after 25 µM. There 
were no differences in terms of GSH depletion observed after 75 µM concentration for both 
CGZ and CSN. Statistical differences were demonstrated between control and test 
compounds (one-way ANOVA, P<0.05) at and above 25 µM. Statistical differences were 
observed between CGZ and CSN at 10, 25 and 50 µM (paired T-test, P<0.05).   
 


























Fig. 34 GSH depletion in THLE-2 cells at varying concentrations of CGZ and CSN. 
Statistical differences were demonstrated between control and test compounds (one-way 
ANOVA, P<0.05) at and above 25 µM. Statistical differences were observed between CGZ 
and CSN at 10, 25 and 50 µM (paired T-test, P<0.05).    
 
 
4.4.4 PC assay 
  
 Finally, we performed PC assay to elucidate the mechanism of toxicity of the TZD 
and PRD analogues using 2,4-dinitrophenylhydrazine as a derivatizing reagent. The results 
related to the PC assay are described below. 
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4.4.4.1 PC assay of TGZ and TSN  
 
Determination of PC was performed in THLE-2 cells after 48 h incubation of TGZ 
and TSN. For each compound, PC (µM) per µg of protein of THLE-2 cells was increased 
from 10 µM of each test compound with respect to control. Significant difference in PC of 
THLE-2 cells was observed at 50 µM between TGZ and TSN (Fig. 35). Statistical differences 
were demonstrated between control and test compounds (one-way ANOVA. P<0.05) and 
between TGZ and TSN (paired T-test, P<0.05) at 50 µM. 
 

































Fig. 35 PC assay of THLE-2 cells at varying concentrations of TGZ and TSN. Statistical 
differences were demonstrated between control and test compounds (one-way ANOVA, 
P<0.05) and between TGZ and TSN (paired T-test, P<0.05) at 50 µM. 
 
4.4.4.2 PC assay of PGZ and PSN  
 
For each compound, PC (µM) per µg of protein of THLE-2 cells was increased from 
10 µM of each test compound with respect to control. Statistical differences were observed 
between PGZ and PSN at 1 and 50 µM (paired T-test, P<0.05) (Fig. 36). Statistical 
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differences were demonstrated between control and test compounds (one-way ANOVA, 
P<0.05) at 50 µM.   
































Fig. 36 PC assay of THLE-2 cells at varying concentrations of PGZ and PSN. Statistical 
differences were demonstrated between control and test compounds (one-way ANOVA, 
P<0.05) at 50 µM. Statistical differences were observed between PGZ and PSN at 1 and 50 
µM (paired T-test, P<0.05).   
 
 
4.4.4.3 PC assay of RGZ and RSN  
 
Determination of PC was performed in THLE-2 cells after 48 h incubation of RGZ 
and RSN. Statistical difference was demonstrated between RGZ and RSN (paired T-test, 



































Fig. 37 PC assay of THLE-2 cells at varying concentrations of RGZ and RSN. Statistical 
difference was demonstrated between RGZ and RSN (paired T-test, P<0.05) at 50 µM. 
 
 
4.4.4.4 PC assay of CGZ and CSN  
 
Determination of PC was performed in THLE-2 cells after 48 h incubation of CGZ 
and CSN. For each compound, PC (µM) per µg of protein of THLE-2 cells was increased 
from 10 µM with respect to control. Statistical difference was observed between CGZ and 
CSN at 10 µM (paired T-test, P<0.05) (Fig. 38) but no difference was observed at 50 µM. 
Statistical differences were demonstrated between control and test compounds (one-way 
ANOVA, P<0.05) at 50 µM.    
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Fig. 38 PC assay of THLE-2 cells at varying concentrations of CGZ and CSN. Statistical 
differences were demonstrated between control and test compounds (one-way ANOVA, 
P<0.05) at 50 µM. Statistical differences were observed between CGZ and CSN at 10 µM 





Effective usage of the TGZ as an antidiabetic agent is limited due to severe liver 
toxicity. Preliminary evidence suggested that the sulfur moiety of the TZD ring might 
contribute as both a toxicophore and pharmacophore. However, a more detailed 
characterization is required to determine the relative contribution of the sulfur moiety to 
toxicity, so as to optimize the clinical usage of existing TZD drugs. In this chapter, we 
attempt to address this issue by comparing the toxic effects of the TZD and PRD analogues.  
 First, we performed independent stability study on each TZD and PRD analogues in 
BEGM up to 72 h. While some succinimide derivatives may be chemically unstable in 
aqueous solution, our data confirmed that the PRD analogues were stable up to 72 h in 
BEGM. It was demonstrated that the TZD analogues were also stable up to 72 h in BEGM. 
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The establishment of the chemical stability of the TZD and PRD analogues in BEGM at 37ºC 
was important to support the result and conclusion of all the subsequent experiments. 
 To link the formation of RMs to the onset of toxicity, we performed MTT cell 
viability assay of both TZD and PRD analogues on the same human hepatocyte cell line, 
THLE-2, that is metabolically-active (Andrea et al., 1993). We had previously demonstrated 
the generation of RMs in THLE-2 cells by the TZD analogues. Consistently, the results in 
this chapter indicated that TGZ and PGZ were more toxic in THLE-2 cells than TSN and 
PSN. Collectively, this was an indirect indication that the sulfur moiety of TGZ and PGZ 
might be partially responsible for liver toxicity in humans. On the other hand, there were no 
significant differences observed between RGZ and RSN, CGZ and CSN in terms of cell 
viability.  
 The next question arose whether TZD analogues exerted any oxidative stress in the 
biological system. To address this question, we further performed MTT assay by co-
incubating 20 µM TA (antioxidant) with both the TZD and PRD analogues at various 
concentrations in THLE-2 cells. By comparing Fig. 25A and 25B, it was clear that TGZ 
produced less toxicity in the presence of TA as compared to TGZ alone. The viabilities of 
THLE-2 cells were 50 and 75% in the absence and presence of TA at 50 µM of TGZ, 
respectively. This might be due to the antioxidant effect of TA which acted as a scavenger for 
potential free radical oxygen species in cells. However, the effect was reversed at higher 
concentrations. On the other hand, the cell viability of THLE-2 cells, when incubated with 
TSN, was clearly less altered in the presence and absence of TA.    
 In another experiment, the results further demonstrated that PGZ was more toxic than 
PSN above 75 µM when the compounds were co–incubated with TA at 20 µM (Fig. 26B). By 
comparing Fig. 26A and 26B, it was clear that PGZ produced less toxicity in the presence of 
TA as compared to PGZ alone. There was no significant difference observed between PSN 
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alone and PSN co-incubated with TA up to 100 µM. This result was possibly due to the 
comparatively lower oxidative stress effect of PSN on THLE-2 cells.  
 Our MTT and RM profiling data collectively suggested that TGZ and PGZ exerted 
oxidative stress on the THLE-2 cells via reactive intermediate formation. On the other hand, 
no significant statistical differences were observed between the other TZD and PRD 
analogues (RGZ and RSN, CGZ and CSN) in the presence or absence of antioxidant. This 
was not unexpected as was previously mentioned that there were no significant differences 
observed between RGZ and RSN, CGZ and CSN in terms of THLE-2 cell viability. 
To further correlate RM formation and toxicity, we performed GSH depletion assay 
using NEM as a derivatizing reagent. Our GSH depletion assay demonstrated that the TZD 
analogues depleted more GSH than the PRD analogues as expected. Using this biochemical 
measurement, we further explained the greater toxicity generated by the TZD analogues as 
compared to their PRD counterparts. Depletion of GSH could either be due to a direct effect 
from the adduction of GSH by reactive intermediates or an indirect effect of oxidative stress 
(perhaps due to mitochondrial dysfunction) resulting in more oxidized GSSG formation. 
While the GSH experiments performed here could not differentiate between these two 
possibilities, our early finding from the MTT assay using TA suggested that TGZ and PGZ 
exerted greater oxidative stress to the human hepatocytes than TSN and PSN. Similarly, RGZ 
and CGZ depleted more GSH as compared to RSN and CSN, respectively, in our GSH 
depletion assay. Collectively, our GSH depletion assay demonstrated that the TZD analogues 
possessed greater GSH depletion capacities than the PRD analogues in THLE-2 cells and 
explained why the TZD analogues produced more toxicity than their PRD counterparts. To 
further confirm the occurrence of oxidative stress, we performed PC assay which 
demonstrated that the TZD analogues generated greater oxidative stress than the PRD 
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analogues. Collectively, oxidative stress appeared to be one likely cause of TZD antidiabetic 
drugs in inducing liver toxicity via reactive intermediate formation.   
 In the following chapter, we shall explore the pharmacological testing of the TZD and 









The sulfur moiety of the TZD ring is an important pharmacophore for the PPARγ 
ligand. This moiety is also partially responsible for hepatotoxicity in humans as confirmed in 
the prevailing chapters of my thesis. Therefore, it becomes important to elucidate whether the 
substitution of the sulfur moiety with the methylene moiety has any direct effect on the 
binding and activation of the PPARγ. The PPARγ is a transcription factor which is expressed 
during glucose and lipid metabolism (Zhang et al., 1992; Kliewer et al., 1992). The PPARγ-
TZD agonist has no direct effect on insulin formation and secretion. They reduce blood 
glucose and triglyceride levels by partially binding to PPARγ in adipocytes (Grossman et al., 
1997). It was demonstrated that the ap2 gene was expressed in 3T3-L1 cells, a cell line that 
had similar morphological and biochemical pattern like human adipocytes (Kliewer et al., 
1992). PGZ and RGZ were shown to increase the expression of the aP2 gene in adipocytes 
which was a region of the PPARγ binding site (Lehmann et al., 1995; Forman et al., 1995). 
 In this chapter, we aimed to compare the PPARγ binding affinities of both the TZD 
and the PRD analogues. Finally, we performed the aP2 gene expression assay which served 




 PolarscreenTM PPARγ competitor red assay kit (with PPARγ-LBD) and superscript® 
III reverse transcriptase assay kit were purchased from Invitrogen Pte Ltd, Singapore. 3T3-L1 
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cell line was purchased from ATCC (Manassas, VA, USA). Microcon YM-30 centrifugal 
filters was purchased from Millipore, Singapore. Methyl tert-butyl ether (MTBE), insulin, 
gentamicin, triazole reagent, dichloromethane (cell culture grade) were purchased from 
Sigma-Aldrich (Saint Louis, MO, USA). Dullbecco’s modified eagle’s media (DMEM) was 
purchased from the National University Medical Store, Singapore. Ribonuclease free water, 
betaine, 10× hot start buffer, magnesium sulfate buffer and hot start DNA polymerase were 
purchased from 1st Base, Singapore. RNeasy mini kit was purchased from Qiagen, Singapore. 
Sybr® green master mix was purchased from Applied Biosystems (Foster city, USA).    
 
5.3 Methods   
 
5.3.1 PPARγ binding assay 
 
5.3.1.1 PPARγ incubation conditions  
 
PPARγ binding assay was performed using PolarscreenTM PPARγ competitor red 
assay kit. In brief, 50 µL of various concentrations of the substrates (both TZD and PRD 
analogues) and 50 µL of PPARγ-LBD were transferred into 384-well plates (black) and co-
incubated in the dark at 37°C. After 24 h, the free unbound drug was extracted using the 
Microcon YM-30 centrifugal filters (Millipore) via centrifugation at 14,000 rpm for 15 min. 
90 µL each of the filtrate was transferred into a clean 1.5 mL microcentrifuge tube and 1 mL 
of MTBE was added. This mixture was vortexed at high speed for 1 min followed by 
centrifugation at 13,000 rpm for 5 min. The MTBE layer was removed and evaporated to 
dryness at 35°C for 1 h under a gentle flow of nitrogen gas using Turbovap LV. The dried 
residue was reconstituted with 50 µL of methanol, vortex-mixed and centrifuged at 13,000 
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rpm for 2 min. 5 µL of the supernatant was subjected to UPLC/MS/MS analysis. 0 h (t0) 
sample was prepared by adding compounds and PPARγ-LBD and immediately removing it 
for filtration via centrifugation. All samples were prepared in triplicates. 
 
5.3.1.1 LC/MS/MS conditions 
 
 For PPARγ binding assay, the LC experimental setup was similar to that we used 
for the profiling of RM-GSH conjugates (Chapter 3). MRM transitions of the TZD and PRD 
analogues (similar to that of the stability studies) were performed in the ESI- and ESI+ mode 
for the PPARγ binding assays (Chapter 4). The MS conditions are summarized in Tables 3 
and 4. For the PPARγ assays, all chromatographic peak area integrations were performed 
using the Analyst Software version 1.4.2 and analyzed statistically using GraphPad Prism 4. 
Statistical differences were analyzed using paired T-test and P<0.05 represented statistically 
significant data.  
 
5.3.2 aP2 gene expression assay 
 
5.3.2.1 3T3-L1 cells 
 
 3T3-L1 cells were maintained in the logarithmic growth phase in DMEM 
supplemented with 10% fetal bovine serum and 25 µg/mL gentamicin, in humidified air with 
5% CO2 at 37°C (according to ATCC guidelines). 1×106 cells/well were seeded in a 10 cm 
petridish and pre-incubated with 5 µg/mL of insulin in DMEM for 24 h. The medium was 
aspirated on the following day and 10 mL of 50 µM of each test compound in DMEM spiked 
with 5 µg/mL of insulin was added and incubated for another 4 days. The medium was 
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replaced every alternate day. Cells containing media with insulin but without test compound 
was employed as control. At the end of the incubation period, the cells were washed with ice-
cold phosphate buffer saline and collected by scraping. Cell pellets were collected by 
centrifuging at 6000 rpm for 1 min at 4ºC. Total ribonucleic anid (RNA) were isolated for 
ap2 gene expression assay.             
 
5.3.2.2 RNA isolation, PCR and qRT-PCR 
 
 Total RNA was isolated from the 3T3-L1 cultured cells by using TriZol reagent and 
RNeasy mini kit. Complementary de-oxyribonucleic acid (cDNA) was prepared from this 
total RNA according to the protocol of reverse transcript system using superscript® III reverse 
transcriptase assay kit for RT-PCR. 
 qRT-PCR was performed using the ABI system (7500 series, Applied Biosystems, 
Foster City, USA) and syber® green PCR master mix. The total volume of reaction mixture 
was 20 µL which contained 2 µL forward and reverse primer in each case (10 µM), 4 µL of 
cDNA (1:10 dilution using ribonuclease free water), 2 µL of ribonuclease free water and 10 
µL of master mix. The cycle program for qRT-PCR was 50°C for 2 min, 95°C for 10 min, 
95°C for 15 sec (repeat 40 times), 60°C for 1 min, 95°C for 0.15 sec (repeat 1 sec), 60°C for 
1 min and 95°C for 0.15 min. The amount of messenger RNA (mRNA) for each ap2 gene 
was normalized according to the amount of mRNA encoding β-actin and calculated in terms 
of ∆Ct values. ∆Ct values were normalized with non-treated control samples for all 
compounds.  
∆Ct = Ctgene of interest – Ctreference gene (β-actin) 
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The reference mRNA was stable throughout the experiment. Relative changes in the 
expression level of one specific gene were calculated in terms of (∆∆Ct) and then presented 
as 2−∆∆Ct (Rebeca et al., 2008).  
∆∆Ct = ∆Cttest – ∆Ctcontrol 
The primer sequences were as follows: β-actin, 5’-GATCTGGCACCACACCTTCT-3’ 
(forward) and 5’-GGGGTGTTGAAGGTCTCAAA-3’ (reverse); ap2, 5’-CAACCTGTGTGA 
TGCCTTTGTG-3’ (forward) and 5’-CTCTCCCTTTGGCTCATGCC-3’ (reverse) (Choi et 
al., 2009).    
 For the ap2 gene expression assay, the generated data were analyzed using the 7500 
system SDS Software version 1.2.3 (Applied Biosystems, Foster City, CA, USA) and 
analyzed statistically using GraphPad Prism 4. Statistical differences were analyzed using 
paired T-test and P<0.05 represented statistically significant data.  
 
5.4 Results  
 
5.4.1 PPARγ binding assay 
 
PPARγ binding assay was performed to evaluate the binding affinities of both the 
TZD and PRD analogues using LC/MS/MS. Determination of both compounds in PPARγ-
LBD samples were performed at 0 and 24 h. PPARγ-LBD-drug stable complex was formed in 
the incubated mixture such that the free drug concentration in the incubated mixture 












Fig. 39 (A) Percentage binding to PPARγ-LBD at varying concentrations of TGZ and TSN. 
Statistical differences were observed between TGZ and TSN in terms of percentage binding 
to PPARγ-LBD at and above 50 nM (paired T-test, P<0.05). (B) Percentage binding to 
PPARγ-LBD at varying concentrations of PGZ and PSN. Statistical differences were 
observed between PGZ and PSN in terms of percentage binding to PPARγ-LBD at 100 nM 









Fig. 40 (A) Percentage binding to PPARγ-LBD at varying concentrations of RGZ and RSN. 
Statistical differences were observed between RGZ and RSN in terms of percentage binding 
to PPARγ-LBD at 50 and 100 nM (paired T-test, P<0.05). (B) Percentage binding to PPARγ-
LBD at varying concentrations of CGZ and CSN. Statistical differences were observed 







As shown in Fig. 39A, TGZ showed higher % binding than TSN at and above 100 
nM. Statistical differences were observed between TGZ and TSN in terms of % binding to 
PPARγ-LBD to PPARγ at and above 50 nM (paired T-test, P<0.05).  
 According to Fig. 39B, it was shown that PGZ had higher % binding than PSN at 100 
and 250 nM. Statistical differences were observed between PGZ and PSN in terms of % 
binding to PPARγ-LBD at 100 nM (paired T-test, P<0.05). 
RGZ had higher % binding than RSN at and above 50 nM (Fig. 40A). Statistical 
differences were observed between RGZ and RSN in terms of % binding to PPARγ-LBD at 
50 and 100 nM (paired T-test, P<0.05). According to Fig. 40B, it was shown that CGZ had % 
higher binding than CSN at and above 250 nM. Statistical differences were observed between 
CGZ and CSN in terms of % binding to PPARγ-LBD at 500 nM (paired T-test, P<0.05).  
 
5.4.2 aP2 gene expression assay  
 
The ap2 gene expression of the TZD analogues was higher than the PRD analogues at 
50 µM concentration in 3T3-L1 cells (Fig. 41 and 42). Although the differences in mRNA 
expressions of the aP2 gene between the TZD and PRD analogues, except TGZ and TSN 
(P<0.05), were not statistically significant (P>0.05), it was clear from our results (Fig. 41 and 
42) that the mean mRNA expression levels between these two chemical classes were 
distinctingly different. Consistently, the TZD analogues led to a greater expression of the aP2 
gene compared to the PRD analogues. A similar trend was observed between TGZ and TSN 
as well (Table 7).  
Importantly, we confirmed that the PRD analogues could bind to the PPARγ ligand to 


























































Fig. 41 (A) Relative amount of mRNA expression of aP2 gene at 50 µM concentration of 
TGZ and TSN. Statistical differences were observed between TGZ and TSN at 50 µM (paired 


































































Fig. 42 Relative amount of mRNA expression of aP2 gene at 50 µM concentration of (A) 





 Given that the sulfur moiety contributes to both adduct formation and toxicity, it 
becomes important to elucidate if the bioisosteric substitution also affect the pharmacological 
effect of the TZD class of antidiabetic drugs. The TZD class of antidiabetic drugs elicits their 
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Table 7 Expression level of mRNA in 3T3-L1 cells (aP2/β-actin) 
 
 
higher % binding to PPARγ-LBD than the PRD analogues, supporting that sulfur moiety is a 
key component of the pharmacophore for PPARγ binding (Khanna et al. 2005).  
It had been established that RGZ has greater % binding to PPARγ-LBD as compared 
to other glitazones. This validated our assay and ensured that the other % binding were 
credible. Our data confirmed that while the PRD analogues lack the sulfur moiety, they could 
still bind to PPARγ. In order to confirm if the binding to the PPARγ by the PRD analogues 
lead to biological activity, aP2 gene expression of each TZD and PRD analogues was further 
measured and compared using qRT-PCR. 
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 The aP2 gene expression assay confirmed again that RGZ yielded the highest aP2 
gene expression among the other glitazones. In parallel, RSN also showed the highest aP2 
gene expression as compared to the other PRD analogues (Table 7). Both the PPARγ binding 
and the aP2 gene expression experiments confirmed that the pyridine ring of each RGZ and 
RSN molecule is an essential pharmacophore that binds and activates the PPARγ ligand in 
addition to the five-membered TZD ring (Khanna et al., 2005; Ramachandran et al., 2004). 
This possibly accounted for the stronger binding affinities and ap2 gene expressions of both 
RGZ and RSN as compared to other glitazones and succinimides.  
More importantly, we determined that the PRD analogues could also bind to the 
PPARγ and stimulate aP2 gene expression. This suggested the potential of the PRD analogues 
to elicit in vivo antidiabetic pharmacological activity. In particular, RSN retained aP2 gene 
expression activity that was comparable to TGZ and PGZ. In summary, our findings 
ascertained the role of the sulfur moiety in eliciting both pharmacological and toxicological 
activity. Nevertheless, other pharmacophoric features besides the TZD ring can partially 
restore PPARγ binding (as seen with RSN) to confer the pharmacological effects. Hence, the 
substitution of the TZD ring by PRD ring is a viable strategy to develop safer PPARγ agonists 











Chapter 6   




TGZS is the major metabolite of TGZ in human plasma (70%) after its oral 
administration (Loi et al., 1997; Loi et al., 1999). TGZS is mainly excreted through bile. The 
proposed mechanism of TGZS toxicity is via the inhibition of BSEP (Funk et al., 2001) 
(Chapter 1).   
Although TGZS has been demonstrated to inhibit BSEP, its direct toxic effect on 
human liver cells has not been investigated. It is important to ascertain this property of TGZS 
as it is a major metabolite of TGZ and its mechanism of direct hepatocyte toxicity remains 
unclear. While it had been determined that TGZS showed no cytotoxicity in human hepatoma 
cell lines such as HepG2, HLE, HLF and HuH–7 cells (Yamamoto et al., 2001), its effect on 
physiologically–relevant normal human hepatocytes has not been established. In this study, 
TGZ and chemically–synthesized TGZS were evaluated for their in vitro toxicity using 
metabolically-active normal human hepatocytes, THLE–2 cells (Andrea et al., 1993; Saha et 
al., 2010).  
 
6.2 Preparation of TGZS (C24H27NO8S2) 
 
6.2.1 Synthesis of methyl-6-hyroxy-2,5,7,8-tetramethylchroman-2-carboxylate [II (A)]  
 
 The synthesis of 6-hyroxy-2,5,7,8-tetramethylchroman-2-carboxylate [II (A)] was 
performed by the method which had been described previously (Chapter 2).     
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6.2.2 Synthesis of (R,S)-2-(hydroxymethyl)-2,5,7,8-tetramethylchroman-6-ol [II (B)] 
 
 The synthesis of (R,S)-2-(hydroxymethyl)-2,5,7,8-tetramethylchroman-6-ol [II (B)] 
was performed by the method which had been described previously (Chapter 2).     
 
6.2.3 Synthesis of [6-(tert-butyl-dimethyl-silanyloxy)-2,5,7,8-tetramethyl-chroman-2-yl]-
methanol [VI (A)]  
 
A mixture of (R,S)-2-(hydroxymethyl)-2,5,7,8-tetramethylchroman-6-ol [II (B)] (2.4 
g, 10.16 mmol), immidazole (0.898 g, 13.20 mmol) and tert-butyldimethylsilyl chloride (3.81 
g, 25.40 mmol) in anhydrous DMF (5 mL) were stirred at RT for 36 h under nitrogen 
atmosphere. Consequently, the mixture was quenched by ice cold water (40 mL) and the 
mixture was extracted with dichloromethane (40 mL, twice). The organic layer was washed 
with brine, dried over anhydrous sodium sulfate and concentrated by evaporation under 
reduced pressure. The concentrate thus obtained was purified by column chromatography on 
silica gel (60-120 mesh) using a mixture of n-hexane/EtOAc (20:1 v/v) as eluent to give a 
colourless viscous oil  [VI (A)] (Fig. 43) (2.2 g, 61% yield). 1H NMR: (CDCl3) δ: 0.12 (s, 6H, 
[-Si(-CH3)2]), 1.05 (s, 9H, [-C(-CH3)3]), 1.22 (s, 3H, -CH3), 1.99-2.06 (m, 2H, -CH2-), 2.07 
(s, 6H, -CH3), 2.11 (s, 3H, -CH3), 2.63 (t, 2H, J= 6 Hz, -CH2-), 3.61 (m, 2H, -CH2-). 13C 
NMR: (CDCl3) δ: 3.33, 3.39, 11.98, 13.39, 14.29, 18.57, 20.34, 20.42, 26.06, 27.81, 69.34, 
75.01, 117.39, 122.59, 123.71, 126.09, 144.55, 145.23 (Fig. 44A). MS (ESI+) m/z (M+H)+ 
351.2. 
 





Sodium hydride (60% in mineral oil, 0.288 g, 12.0 mmol) and [6-(tert-butyl-dimethyl-
silanyloxy)-2,5,7,8-tetramethyl-chroman-2-yl]-methanol (2.1 g, 6.0 mmol) in anhydrous 
DMF (20 mL) was stirred for 30 min under nitrogen atmosphere at RT. Subsequently, 4-
fluorobenzaldehyde (1.3 mL, 12.0 mmol) was added slowly dropwise to the reaction mixture 
under nitrogen atmosphere at RT. After stirring at the same temperature for overnight, the 
reaction mixture was quenched with aqueous ammonium chloride (20 mL). Ice-water (30 
mL) was added to the reaction mixture and the resultant mixture was extracted with EtOAc 
(50 mL, two times). The organic layer was washed with water and brine, dried over 
anhydrous sodium sulfate and concentrated by evaporation under reduced pressure. The 
concentrate thus obtained was purified by column chromatography on silica gel (60-120 
mesh) using a mixture of n-hexane/EtOAc (4:1 v/v) as eluent to give a yellow liquid [VI (B)] 
(Fig. 43) (0.45 g, 22.05% yield). 1H NMR: (CDCl3) δ: 0.85 to 0.94 (m, 2H, -CH2-), 1.28 (s, 
3H, -CH3), 1.96 (s, 3H, -CH3), 1.98 (s, 3H, -CH3), 2.12 (s, 3H, -CH3), 2.69 (t, 2H, J= 6 Hz, -
CH2-), 3.63 (m, 2H, -OCH2-), 6.85 (d, 2H, J= 9 Hz, -C6H4-), 7.77 (d, 2H, J= 9 Hz, -C6H4-), 
9.84 (s, 1H, -CHO). MS (ESI+) m/z (M+H)+ 341.1. 
 
6.2.5 Synthesis of (R,S)-5-[4-(6-hydroxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-benzyl]-
thiazolidine-2,4-dione [VI (C), TGZ]  
 
A mixture of 4-(6-hydroxy-2,5,7,8-tetramethyl-chroman-2-ylmethoxy)-benzaldehyde 
(420 mg, 1.23 mmol) and TZD (128 mg, 1.10 mmol) in anhydrous ethanol (20 mL) were 
heated under reflux for 24 h in presence of few drops of 2-aminoethanol and then cooled to 
RT. The reaction mixture was concentrated by evaporation under reduced pressure. A solid 
compound was obtained and 25 mL hexane was added to dissolve excess aldehyde. The solid 
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compound was filtered, dissolved in excess ethanol and a reduction step was performed 
without further purification. The above-mentioned ethanol was taken in a parr bottle and 50 
mg of Pd/C (10%) was added to it. The compound was hydrogenated under hydrogen 
atmosphere (pressure 40 psi) at RT for 8 h. The mixture was filtered using celite and 
concentrated by evaporation under reduced pressure to give a white solid. The compound was 
further purified by column chromatography on silica gel (60-120 mesh) using a mixture of n-
hexane/EtOAc (10:1 v/v) as eluent to give a white solid [VI (C)] (Fig. 43) (0.256 g, 47.05% 
yield). Melting point 182°C (Literature value 184°C) (Lee et al., 2005). 1H NMR: (DMSO-
d6) δ: 1.28 (S, 3H, -CH3), 1.77-1.83 (m, 1H, -CH2-), 1.97 (s, 3H, -CH3), 2.02 (s, 3H, -CH3), 
2.04 (s, 3H, -CH3), 2.05-2.08 (m, 1H, -CH2-), 2.56 (t, 2H, J = 6 Hz, -CH2-), 3.00-3.08 (m, 1H, 
-OCH2-), 3.25-3.30 (m, 1H, -OCH2-), 3.93 (d, 2H, J = 12 Hz,  -CH2-), 4.83 (t, 1H, J = 6 Hz, -
CH=), 6.88 (d, 2H, J= 9Hz, -C6H4-), 7.11 (d, 2H, J= 9 Hz, -C6H4-), 7.42 (s, 1H, -OH), 11.99 
(s, 1H, -NH). 13C NMR: (DMSO-d6) δ: 12.83, 13.78, 20.80, 22.79, 29.31, 37.29, 39.72, 
54.06, 73.49, 74.78, 115.67, 117.76, 121.36, 122.12, 123.77, 129.81, 131.35, 145.14, 146.44, 
158.91, 172.73, 176.74 (Fig. 44B). MS (ESI-) m/z (M-H)- 440.1. 
 
6.2.6 Synthesis of (R,S)-sulphuric acid mono-{2-[4-(2,4-diox-thiazolidin-5-ylmethyl)-
phenoxymethyl]-2,5,7,8-tetramethyl-chorman-6-yl} ester [VI (D), TGZS]  
 
A mixture of TGZ (0.25 g, 0.56 mmol), sulphur trioxide-N-triethylyamine complex 
(0.135 g, 0.84 mmol) and potassium carbonate (0.234 g, 1.70 mmol) in 50 mL anhydrous 
DMF was agitated for 1 h at RT in argon atmosphere. The reaction mixture was placed in 
water bath (40ºC) for 2 h, after which TGZS was precipitated out and stuck to the surface of 
glass. DMF layer was decanted out and precipitated TGZS was recrystalized with methanol 
(5 mL) and dried under vacuum at 40°C to give as a yellow solid [VI (D)] (Fig. 43) (0.008 g, 
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2.7% yield, 99.2% purity). Melting point 189°C. 1H NMR: (DMSO-d6) δ: 1.28 (S, 3H, -CH3), 
1.77-1.83 (m, 1H, -CH2-), 1.97 (s, 3H, -CH3), 2.02 (s, 3H, -CH3), 2.04 (s, 3H, -CH3), 2.05-
2.08 (m, 1H, -CH2-), 2.09 (s, 1H, -SO3H), 2.56 (t, 2H, J = 6 Hz, -CH2-), 3.00-3.08 (m, 1H, -
OCH2-), 3.25-3.30 (m, 1H, -OCH2-), 3.93 (d, 2H, J = 12 Hz,  -CH2-), 4.83 (t, 1H, J= 6 Hz, -
CH=), 6.88 (d, 2H, J= 9Hz, -C6H4-), 7.11 (d, 2H, J= 9 Hz, -C6H4-), 11.99 (s, 1H, -NH). 13C 
NMR: (DMSO-d6) δ: 12.85, 13.78, 20.80, 22.77, 29.30, 31.72, 37.27, 54.06, 73.45, 74.78, 
115.66, 117.77, 121.36, 122.12, 123.77, 129.80, 131.36, 145.14, 146.42, 158.90, 172.77, 





















                                 
                                                                                                                





                                                                                                 
                                                                    




















Fig. 43 Synthesis of TGZS. (A) Tert-butyldimethylsilyl chloride, immidazole, anhydrous 
DMF, RT, 36 h; (B) sodium hydride, anhydrous DMF, 4-flurobenzaldehyde, RT, 12 h; (C) 
TZD, 2-aminoethanlol, reflux, 24 h and then 10% Pd/C, H2 gas, EtOH, 12 h; (D) sulphur 
trioxide-N-triethylyamine complex, potassium carbonate, anyhydrous DMF, RT for 1h then 































































































































Fig. 44 13C NMR interpretation (A) 6-(tert-butyl-dimethyl-silanyloxy)-2,5,7,8-tetramethyl-











6.3.1 Sulfotransferase enzyme inhibition assay 
 
6.3.1.1 THLE-2 cells incubation 
 
THLE–2 cells were seeded into a 6-well plate (1.0×107 cells/well). 100 µM of either 
TGZ alone or TGZ and quercetin (QR) in combination were added to the cells and the 
mixtures were incubated under a humidified condition with 5% CO2 at 37°C. QR is a phenol 
sulfotransferase enzyme inhibitor and its concentration used in each incubation was 50 µM. 
The final concentration of the test compounds and organic solvent were 50 µM and 0.2% 
(v/v), respectively. After 24 h (t24), the reaction was terminated by addition of 2 mL of ice 
cold ACN/water (50:50 v/v). Initial time point samples (t0) were prepared by terminating the 
reaction immediately after adding the test compound to the THLE–2 cells with same 
quenching solvent. These samples were centrifuged at 13,000 rpm at 4°C for 10 min and the 
supernatants were removed and evaporated to dryness at 35°C for 8 h under a gentle flow of 
nitrogen gas using the Turbovap LV. Then, they were each reconstituted with 50 µL of 
ACN/water (50:50 v/v), vortex-mixed and centrifuged at 13,000 rpm at 4°C for 2 min. 5 µL 
of the supernatant was subjected to UPLC/MS/MS analysis. Negative control experiments 
were also performed in the absence of THLE-2 cells or substrates. 
 
6.3.1.2 LC/MS/MS conditions  
 
For the profiling of sulfotransferase enzyme inhibition assay of both TGZ and QR 
using THLE–2 cells, chromatographic separations were performed on an ACQUITY UPLC 
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BEH C18 1.7 µm 100 × 2.1 mm i.d. column (Waters). The flow rate was set at 0.5 mL/min.  
The elution conditions were similar to the profiling of RM-GSH conjugates (Chapter 2). ESI– 
mode was employed throughout the experiments. MRM transition and single ion monitoring 
(SIM) were performed at m/z 520.0→440.0 for TGZS and m/z 381.0 for quercetin sulfate 
(QRS), respectively. The MS conditions are summarized in Table 8.  
 The common parameters of MS for TGZS and QRS were as follows: curtain gas 
(CUR); 10 psi, ion spray voltage; -4500 V, collision gas (CAD); medium, ion source gas 
(GS1); 40 psi, ion source gas (GS2); 45 psi, interface heater; On, temperature; 500°C, scan 
time; 250 ms.  
 
Parameters TGZS QRS 
Declustering potential, V –49.0 55.0 
Entrance potential, V –5.6 –4.5 
Collision cell entrance potential, V –30.0 Nil 
Collision energy, V –4.0 Nil 
 




6.3.2 Stability study of synthesized TGZS in BEGM 
 
 Stability study was performed by the method which had been described previously 





6.3.3 MTT viability assay 
 
 MTT viability assay was performed by the method which had been described 
previously (Chapter 4). In another experiment, both TGZ and TGZS (1-125 µM) were 
incubated with THLE-2 cells in absence and presence of TA (Chapter 4). In a separate 
experiment, 50 µM QR was co–incubated with TGZ and TGZS at varying concentrations (1–
125 µM) in THLE–2 cells (Virginia et al., 2004). In parallel, another cell viability assay was 
performed using various concentrations of QR (1–125 µM) in THLE–2 cells in the absence 
of TGZ and TGZS. 
 
6.3.4 GSH depletion assay 
 
 GSH depletion assay was performed by the method which had been described 
previously (Chapter 4).  
 
6.3.5 PC assay 
 
 PC assay was performed by the method which had been described previously 
(Chapter 4).  
 
 6.4 Results 
 
6.4.1 Sulfotransferase enzyme inhibition assay 
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 LC/MS/MS analysis of THLE–2 cells incubation with TGZ revealed the presence of 
TGZS using MRM at m/z 520.0→440.0. The MRM experiment confirmed the presence of 






Fig. 45 (A) Representative LC/MS/MS chromatogram of TGZS in “24 h TGZ–THLE–2” 
sample (retention time 4.92 min). (B) Representative LC/MS/MS chromatogram of “24 h 




THLE–2” and negative control samples but present in “24 h TGZ–THLE–2” incubation. 
TGZS is the sulfo–conjugate of TGZ where the conjugation with the bi–sulfate (-OSO3H) 
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absent when TGZ and QR (“24 h TGZ–QR–THLE–2”) were co-incubated with THLE–2 
cells for 24 h (data not shown). The absence of TGZS in the “24 h TGZ–QR–THLE–2” 
sample indicated that sulfotransferase enzyme activity blocked by QR. As shown in Fig. 45B, 
SIM at m/z 381.0 of the “24 h TGZ–QR–THLE–2” sample exhibited the presence of 
quercetin sulfate–1 (QRS1, retention time 3.09 min) and quercetin sulfate–2 (QRS2, retention 
time 6.68 min). The presence of QRS1 and QRS2 in the “24 h TGZ–QR–THLE–2” sample 
confirmed the competition of QR for the sulfotransferase enzyme. 
 
6.4.2 Stability profile of TGZS using BEGM 
 
 To evaluate the contribution of the sulfo-conjugate to direct hepatotoxicity and 
mitigate the possible confounding factors coming from parental TGZ through hydrolysis of 
TGZS, we performed stability assessment of TGZS in our cell culture conditions. The 
stability study demonstrated that TGZS at 1.0 (86.02%) and 50 µM (95.53%) was stable up to 
72 h in BEGM at 37ºC (Fig. 46). The stability ranges were 100 ± 15% up to 72 h for TGZS. 
The levels of TGZS among the different time points (0, 24, 48 and 72 h) were not 
significantly different.  
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6.4.3 MTT viability assay  
  
THLE–2 cells were treated with TGZ and TGZS at various concentrations (1–125 
µM) for 72 h. As shown in Fig. 47A, cell viability of the hepatocytes was dose–dependent for 
both TGZ and TGZS where an increase in dose of each test compound was associated with a 
consistent decline of cell viability. It was shown that when each compound was incubated 
with THLE–2 cells, toxicity was observed from 1 µM with respect to control in both cases.  
However, the observed toxic effect of TGZS was greater than TGZ after 1 µM. The THLE–2 
cell viability was 50% at 75 µM of TGZ and remained unchanged up to 125 µM. On the 
other hand, cell viability decreased dramatically when dosed with TGZS and was below 10% 
at and above 50 µM of TGZS. The calculated EC50 for TGZS and TGZ were 21.76 ± 5.34 
and 41.12 ± 4.3 µM, respectively. Statistical differences were demonstrated between control 
and test compounds (one–way ANOVA, P<0.05) and between TGZ and TGZS (paired T–
test, P<0.05) at and above 10 µM concentration, respectively. 
To inhibit the biotransformation of TGZ to TGZS by sulfotransferase enzyme in 
THLE–2 cells, we co–incubated both compounds (TGZ and TGZS) with 50 µM of QR. Our 
results demonstrated that TGZS was more toxic than TGZ at and above 50 µM when co–
incubated with QR (Fig. 47B). Statistical differences were observed between TGZ and TGZS 
in terms of percentage cell viability at and above 50 µM (paired T–test, P<0.05). It was also 
confirmed that the viability of THLE–2 cells was not affected by QR alone up to a 
concentration of 125 µM (data not shown). QR is a naturally occurring flavonoid having 
hepatoprotective activity (Gulati et al., 1995).    
To determine if the increased cytotoxicity of TGZS was linked to oxidative stress, we 
co–incubated both treatments with the antioxidant, TA. The results further demonstrated that 







































































Fig. 47 (A) Percentage MTT cell viabilities of THLE–2 cells at varying concentrations of 
TGZ and TGZS. Statistical differences were demonstrated between control and test 
compounds (one–way ANOVA, P<0.05) and between TGZ and TGZS (paired T–test, 
P<0.05) at and above 10 µM concentration, respectively. (B) Percentage MTT cell viabilities 
of THLE–2 cells at varying concentrations of TGZ and TGZS co–incubated with 50 µM of 
QR. Statistical differences were observed between TGZ and TGZS in terms of percentage 
cell viability at and above 50 µM (paired T–test, P<0.05). (C) Percentage MTT cell viabilities 
of THLE–2 cells at varying concentrations of TGZ and TGZS co–incubated with 20 µM of 
TA. Statistical differences were observed between TGZ and TGZS in terms of percentage cell 
































Fig. 48 Percentage MTT cell viabilities of THLE–2 cells at varying concentrations of QR. 
 
TA at 20 µM level (Fig. 47C). Statistical differences were observed between TGZS and TGZ 
in terms of percentage cell viability at and above 25 µM (paired T–test, P<0.05). By 
comparing Fig. 47A and 47C, it was clear that TGZS produced less toxicity in the presence of 
TA as compared to TGZS alone. The viabilities of THLE–2 cells were 20 and 50% in the 
absence and presence of TA at 25 µM of TGZS, respectively. As an experimental control, we 
confirmed that the viability of THLE–2 cells was not affected by TA alone up to a 
concentration of 100 µM (Fig. 48).   
 
6.4.4 GSH depletion assay  
 
Determination of GSH–NEM adducts was performed in THLE–2 cells after 72 h 
incubation with TGZ and TGZS to measure any depletion of GSH. A linear regression 
































Fig. 49 GSH depletion in THLE–2 cells at varying concentrations of TGZ and TGZS. 
Statistical differences were demonstrated between control and test compounds (one–way 
ANOVA, P<0.05) and between TGZ and TGZS (paired T–test, P<0.05) at and above 50 µM, 
respectively. 
 
The accuracy of the assay was found to be within 80 to 108%. The recoveries of the GSH–
NEM complex in QC samples were 60 to 80%, respectively. The RT for GSH–NEM complex 
was 3.13 min. GSH depletion (µM) per µg of protein was measured at varying concentrations 
of TGZ and TGZS after 72 h (Fig. 49). As shown in Fig. 49, TGZS depleted more GSH than 
TGZ after 50 µM. Statistical differences were demonstrated between control and test 
compounds (one–way ANOVA, P<0.05) and between TGZ and TGZS (paired T–test, 
P<0.05) at and above 50 µM, respectively. 
 
6.4.5 PC assay  
 
Determination of PC content was performed in THLE–2 cells after 48 h incubation 
with TGZ and TGZS as a surrogate for ROS-mediated protein oxidation. For each compound, 
PC content (µM) per µg of protein of THLE–2 cells was increased at all concentrations 








































Fig. 50 PC assay of THLE–2 cells at varying concentrations of TGZ and TGZS. Statistical 
differences were demonstrated between control and test compounds (one–way ANOVA, 
P<0.05) and between TGZ and TGZS (paired T-test, P<0.05) at 50 µM. 
 
demonstrated between control and test compounds (one–way ANOVA, P<0.05) and between 
TGZ and TGZS (paired T–test, P<0.05) at 50 µM. 
  
6.5 Discussion  
 
 In the chapters 3 and 4, we observed that the TZD ring of glitazones might be 
responsible for oxidative stress in THLE-2 cells via RM formation. We addressed that phase I 
metabolism is directly related to cytotoxicity in the subsequent chapters. In this chapter, we 
have discussed another issue about the cytotoxic effect of drug after phase II metabolism. 
Preliminary evidences suggested that the potential mechanism of hepatotoxicity of TGZS 
might be due to inhibition of BSEP (Smith, 2003). Therefore, it remains unclear if the sulfo-
conjugated metabolite (TGZS) of TGZ has direct toxic effect on human liver cells. In the 
current chapter, the aim was to ascertain and establish the role of TGZS in causing direct 
toxicity in human hepatocytes.  
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 To achieve this goal, TGZS was synthesized where 6–hydroxyl (–OH) group of TGZ 
was replaced by bi–sulfate (–OSO3H) group. In this study, the cytotoxicities of TGZS and 
TGZ were compared using THLE–2 cells, normal human hepatocytes with metabolizing 
capacity. The MTT assay results confirmed that TGZS was more toxic in human hepatocytes 
than TGZ. This data suggested a novel mechanism of toxicity of TGZ where TGZS is a direct 
toxicant in humans. In order to elucidate the cytotoxic effects of TGZ and TGZS more 
accurately, MTT assay was further performed where the sulfonation of TGZ to TGZS in 
THLE-2 cells was inhibited using QR, a specific phenol sulfotransferase inhibitor (Virginia et 
al., 2004). QR prevented the sulfonation of TGZ which was confirmed by LC/MS/MS 
experiments. Due to inhibition of sulfotransferase enzyme activity by QR, we observed 
toxicities of TGZ and TGZS individually in THLE-2 cells. MTT data using co–incubation of 
our test compounds with QR further supported that TGZS was more toxic than TGZ in the 
absence of biotransformation of TGZ to TGZS during incubation.  
 Based on earlier reports that TGZ mediated hepatotoxicity in part through generating 
oxidative injury (Smith, 2003), we raised the question whether the observed cytotoxicity was 
related to TGZS–induced oxidative stress in the biological system. To answer this question, 
MTT assay was performed by co–incubating 20 µM TA with TGZ and TGZS at various 
concentrations in THLE–2 cells. The data demonstrated that cell viability was improved 
when TGZS was co–incubated with TA. The partial salvation of human hepatocytes from the 
toxic effects of TGZS by an antioxidant indicated indirectly that TGZS might have exerted 
oxidative stress on the THLE–2 cells. In line with this observation, the GSH depletion assay 
established that TGZS depleted more GSH than TGZ, further underscoring the oxidative 
stress potential of TGZS. To further characterize the targets of oxidative stress, we performed 
PC assay which demonstrated that TGZS generated greater oxidation on cellular proteins than 
TGZ. Collectively, TGZS appeared to cause human liver toxicity by inducing oxidative 
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stress. Finally, the stability study confirmed that TGZS was stable in BEGM at 37ºC up to 72 
h. This finding was important to rule out the possibility of TGZS undergoing deconjugation 
to TGZ during incubation. Hence, we were able to attribute all observed toxicity effects to 
TGZS accurately. 
The human blood concentration of TGZ is 0.3–0.5 µg/mL or 7–12 µM after oral 
administration (Loi et al., 1999). Our MTT, GSH and PC assays demonstrated that TGZS was 
more toxic towards THLE–2 cells at and above 10 µM concentration as compared to parent 
TGZ. As the pharmacological and in vitro concentrations of TGZ and TGZS are in the same 
dynamic order of magnitude, it suggested that the investigated in vitro concentrations of 
TGZS (1–125 µM) were clinically–relevant and associated with the human physiological 
concentrations.  
This study yielded a surprising outcome in the light of some earlier works. Using 
primary cultures of human hepatocytes, Kostrubsky et al. (2000) proposed that TGZ was 
responsible for cytotoxicity rather than its metabolite TGZS. It was reported that inhibition of 
sulfation in these hepatocytes resulted in an accumulation of parent TGZ and cytotoxicity. 
Nonetheless, their findings were not confirmed using pure chemically–synthesized TGZS. 
Sulfo–conjuation is an essential metabolic pathway for many drugs, xenobiotics and 
endogenous substances. While the main role of sulfo–conjugation is to enhance the 
hydrophilicity of drugs and aid their excretion from the body, it has been reported that 
sulfation of certain allylic alcohols and polycyclic aromatic hydrocarbons may produce 
metabolites with increased toxicity (Chou et al., 1998; Banoglu, 2000; King et al., 2000). We 
reported for the first time that TGZS, a sulfo–conjugate of TGZ, exerted direct toxic effects 
on human hepatocytes, possibly via oxidative stress induction. It is noted that some phase II 
metabolites such as indoxyl sulfate, a sulfate metabolite of 3–hydroxyindole, causes renal 
failure via unknown mechanism (Banoglu and King, 2002). Similarly, the toxic mechanism 
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of TGZS is unknown. However, as both TGZ and TGZS had been shown to bind to similar 
biological receptor such as BSEP (Funk et al., 2001), it is possible that these compounds may 
bind to other similar biological receptors leading to oxidative stress and cell death. As TGZS 
is a major metabolite of TGZ in humans, the differential extent of phase II sulfation of TGZ 
in diabetic patients may be accountable for the idiosyncratic nature of TGZ–induced 
hepatotoxicity. 
In summary, our present study reinforced the concept that hepatotoxicity of TGZ is 
possibly related to multiple mechanisms (Smith, 2003). Sulfonation at the 6–hydroxyl group 
of the chroman ring of TGZ is a potential cause of TGZ–induced hepatotoxicity. In addition 
to bile salt accumulation via inhibition of BSEP, we confirmed that TGZS is a direct human 
hepatotoxicant. Prospective studies involving other normal human hepatocytes, collagen–
sandwiched hepatocytes, human liver slices and animal models are needed to confirm the 
interplay between the dual toxic mechanisms of TGZS.  
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Chapter 7  
Conclusion and future direction  
 
7.1 Conclusion  
 
The work presented in this thesis described the STR studies of the TZD antidiabetic 
drugs. The PRD analogues were prepared and examined for potential mechanism of toxicity 
using THLE-2 cells. Comparisons of toxicities of these compounds (both the TZD and PRD 
analogues) were also performed using THLE-2 cells. The sulfur moiety of the TZD ring was 
determined to be partially responsible for hepatotoxicity via the formation of reactive 
intermediates. These intermediates were detected in HLM and THLE-2 cells using GSH-
trapping LC/MS/MS technique. No such intermediates were detected with regards to the PRD 
analogues. These findings suggested that the sulfur moiety was responsible for the RM 
formation either directly or indirectly.  
A question arose whether TZD antidiabetic drugs produced toxicity via oxidative 
stress mechanism. To address this question, we performed MTT, GSH and PC assays. The 
MTT assay results confirmed that the TZD analogues, particularly TGZ and PGZ, produced 
greater toxicity than the PRD analogues in THLE-2 cells. TA-enriched MTT, GSH and PC 
assays were further performed to elucidate the mechanism of toxicity. MTT assay using TA 
(antioxidant) demonstrated that all the TZD analogues produced lesser toxicity than TZD 
alone. One possibility was that TA acted as a free radical oxygen scavenger and quenched the 
free oxygen species in the incubation system. In line with this observation, our GSH 
depletion assay further confirmed that all the TZD analogues depleted more GSH than the 
PRD analogues, further underscoring the oxidative stress capacity of the former. Finally, our 
PC assay exhibited the generation of more PC by the TZD analogues when compared to the 
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PRD analogues, confirming the occurrence of oxidative stress, In conclusion, the TZD 
antidiabetic drugs produce hepatotoxicity via oxidative stress mechanism mediated through 
the formation of RMs.  
Our present study also focussed on the PPARγ binding affinities of the TZD and PRD 
analogues to elucidate the importance of the sulphur moiety in binding to the receptor. Our 
PPARγ binding assay depicted that both the TZD and PRD analogues had binding affinities to 
the PPARγ. As expected, the TZD analogues showed higher binding affinities to the PPARγ 
than the PRD analogues. Hence, the sulfur moiety was confirmed to be an important 
pharmacophore for the PPARγ ligand. The results of the aP2 gene expression assay 
demonstrated expression of the gene by both types of analogues. While the TZD analogues 
expressed more aP2 gene than the PRD analogues, we confirmed that the PRD analogues 
possessed PPARγ binding affinities and aP2 gene expression capacities. As both types of 
analogues were shown to bind to the PPARγ and express the aP2 gene, the substitution of the 
TZD ring with PRD ring may be beneficial from a drug design perspective.  
For a holistic STR study, we prepared sulfo–conjugated troglitazone (TGZS) 
synthetically and tested its toxicity using THLE–2 cells. Our MTT, GSH and PC results 
suggested that TGZS was more toxic than its parent TGZ and may be partially responsible for 
TGZ–induced hepatotoxicity via oxidative stress mechanism.    
In conclusion, the PRD analogues demonstrated reduced toxicity in THLE-2 cells 
while sustaining the abilities to bind to the PPARγ and stimulate aP2 gene expression. In 
particular, RSN retained aP2 gene expression activity that was comparable to that TGZ and 
PGZ. The substitution of the TZD ring by PRD ring is a viable strategy to develop safer 





7.2 Limitation and future direction 
 
The present study restricts the use of other oxidative stress assay like lipid 
peroxidation assay to prove oxidative stress mechanism strongly. Attempts should be made to 
investigate why this assay did not give positive results during our screening. TZD class of 
antidiabetic drugs may produce hepatotoxicity via multiple mechanisms (Smith, 2003). 
Oxidative stress may be another potential cause of hepatotoxicity. Lipid peroxidation assay 
gives strong measurement for oxidative stress. Future attempts should be made to investigate 
why this assay did not give positive results during our screening of the TZD compounds and 
PRD analogues. Future studies should also include animal experiments to further elucidate 
the exact mechanism of toxicity in vivo. The use of PRD analogues alone might not explain 
the mechanism of toxicity of the TZD drugs in this project completely. Future studies should 
explore other bio-isosteric analogues containing 2,4-oxazolidinedione in place of PRD to 
investigate their pharmacological and toxicological profiles. Finally, further investigation 
such as enantiomeric separation of synthesized racemic analogues and testing of each chiral 
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